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1. Abbreviations 
3’UTR  Three prime untranslated region 
ADCC Antibody-dependent cell-mediated cytotoxicity 
ADAM A disintegrin and metalloproteinases  
ADAMTS A disintegrin and metalloproteinase with thrombospondin motifs 
APP Amyloid precursor protein 
ATM/ATR Ataxia-telangiectasia mutated and ATM- and Rad3-related kinases 
BACE Beta-secretase 1 
CHO Chinese hamster ovary  
CIK Cytokine induced killers 
CMV Cytomegalovirus 
DAP10 DNAX-activating protein 
DLL1 Delta-like protein 1 
ELISA Enzyme-linked immunosorbent assay 
ERK Extracellular-signal-regulated kinases 
FC Flow cytometry 
Grb2 Growth factor receptor-bound protein 2 
HDAC Histone deacetylase 
HCMV Human Cytomegalovirus 
IE1/IE2 Immediate early gene products 1 and 2 
IC Intracellular 
INF Interferon 
INF- Interferon gamma 
IP Immunoprecipitation 
MCA Methylcholanthrene 
MEK Mitogen-activated protein kinase kinase 
MICA MHC class I chain-related molecule A 
MICB MHC class I chain-related molecule B 
MMP Matrix metalloproteinase 
MULT1 Murine ULBP-Like transcript 1 
NCR Natural cytotoxic receptor 
NF-Y Nuclear transcription factor Y 
NKG2D Natural killer group 2D 
PI3K Phosphatidylinositol 3-kinases 
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PMA Phorbol 12-myristate 13-acetate 
RAET Retinoic acid early transcript protein 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SiRNA Small interfering RNA  
Sp1, 3 Specificity Protein 1 and 3 
SVMPs Snake venom metalloproteinases 
TGF- Transforming growth factor alpha 
TLR Toll-like receptor 
TNF- Tumor necrosis factor alpha 
TRAMP Transgenic adenocarcinoma of the mouse prostate model 
tPA Tissue plasminogen activator 
TSA Tumor specific antigen 
ULBP UL16-binding protein 
uPA Urokinase-type plasminogen activator 
WB Western blotting 
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2. Introduction 
2.1 Cancer and the immune System 
Scientific evidence has proven the important role of the immune system in the prevention of 
malignant transformation. In the process referred to as tumor immunosurveillance the immune 
system can specifically recognize and destroy transformed cells based on the expression of tumor 
specific antigens (TSA) or stress-induced molecules. The adaptive immune system with its effector 
-T cells can recognize tumor antigens in the context of major histocompability (MHC) molecules 
and effectively eliminate transformed cells. However, the innate immune system with its effector 
cells (NK, NKT, -T cells) can recognize “stress-induced” danger signals without MHC presentation 
and eliminate transformed cells before the acquired, adaptive immune system starts to function  
(Murphy et al, 2008).  Many types of cancer cells selectively downregulate MHC class I molecules on 
the cell surface (Khanna, 1998) and in these cases, an anti-stress response of the innate immune 
system might be of particular importance  in tumor immunosurveillance.  
2.2 NK cells  
A prototypical example of leukocytes sensing different forms of cellular stress are natural killer (NK) 
cells. Initially, NK cells were described as large granular lymphocytes with natural cytotoxicity against 
tumor cells (Kiessling et al., 1975). NK cells are major effectors of the innate immune system 
combining both cytotoxic and cytokine-producing effector functions. They develop mainly in the 
bone marrow and circulate in the peripheral blood (2-18% of lymphocytes) (Cooper et al., 2001). The 
cytotoxic potential of NK cells is mainly based on the release of granules containing perforin and 
granzymes (Trinchieri, 1989). They are activated upon type I interferons (INF) as well as IL-2, IL-12, IL-
15 and IL-18. Following activation, NK cells produce INF- and TNF- (Vivier et al., 2008).  
The main targets of NK cells are “altered self” cells that experienced various forms of cellular stress 
(DNA damage-related stress, malignant transformation, microbial infection) (Luci and Tomasello, 
2008). The wide range of inhibitory and activating receptors expressed on NK cells enables the 
discrimination between potentially dangerous target cells from healthy cells. The recognition of self 
MHC class I molecules by inhibitory NK cell receptors (killer cell immunoglobulin like receptors (KIR) 
and lectin-like CD94-NKG2A heterodimers) provides a negative signal leading to tolerance, whereas 
the ligation of killer activating receptors such as natural killer (NK) group 2D (NKG2D) and natural 
cytotoxic receptors (NCR) transmits a positive signal that elicits the activation of NK cells (Vivier et al., 
2008). The balance between these negative and positive signals defines the activation status of NK 
cells (Fig.1).  
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Fig.1 (A) Cells expressing self MHC class I molecules and low amounts of stress-induced molecules are 
tolerated by NK cells. (B) NK cells selectively target cells in “distress” that downregulated inhibitory 
MHC class I molecules or upregulated stress-induced self molecules on the cell surface (Vivier et al., 
2011). 
2.3 NKG2D receptor 
NKG2D is the best studied activating receptor expressed on NK cells, NKT cells, T cells, CD8+ T cells 
and on some CD4+ T cells. Depending on the cell type NKG2D serves either costimulatory or direct 
activatory function. In TCR-activated CD8+ T cells NKG2D has a costimulatory function (Raulet, 2003) 
while in  T cells NKG2D might trigger both costimulatory or primary activatory pathways (Rincon-
Orozco et al., 2005). In NK cells the ligation of NKG2D directly elicits activating signals inducing 
cytotoxic effector function (Raulet, 2003).  
The NKG2D receptor gene is located in the NK gene complex on chromosome 12 in humans and on 
chromosome 6 in mice. NKG2D is a homodimeric type II transmembrane protein with a short 
cytoplasmic tail. For signal transduction each homodimer of NKG2D associates with 2 adaptor 
molecules of DNAX-activating protein of 10kD (DAP10) in human and with DAP10 or DAP12 in mice.  
DAP10 contains a YINM signaling motif and the phosphorylation of the YINM motif by Src family 
kinases leads to the recruitment of the p85 subunit of PI3-K and Grb2 to DAP10. This results in the 
activation of a PI3K-Vav1-Rac-PAK1-MEK-ERK signaling cascade essential for the release of cytotoxic 
granules and for NK cell effector functions in humans. However, the molecular details of this signal 
transduction pathway remain to be elucidated (Coudert and Held, 2006). 
2.4 The ligands for the NKG2D receptor  
A hallmark of the NKG2D receptor is the multitude of ligands identified so far (Gonzalez et al., 2008). 
These include MHC class I chain-related molecules A and B (MICA/B) and the UL 16-binding protein 
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(ULBP) family with its members ULBP1-6 in humans (Champsaur and Lanier, 2010). In the murine 
system no MIC molecules but 7 member of the RAET family (5 retinoic acid early transcripts 1 (RAE1) 
proteins, H60 and MULT1) have been identified as the ligands for the NKG2D receptor (Cerwenka et 
al., 2000). Since this study concerns human MICA and MICB molecules, these molecules will be 
described in more detail.  
MIC genes are localized within the human HLA locus. Like classical MHC class I molecules (homology 
28-35%) MIC proteins contain 3 extracellular Ig-like domains , a transmembrane domain and 
a short cytoplasmic tail (Fig.2). They are highly polymorphic and the different allelic variants are 
expressed co-dominantly (Stephens, 2001). To date 84 alleles of MICA and 35 alleles of MICB have 
been identified, which results in encoding 67 and 23 variants of MICA and MICB proteins, respectively 
(http://www.ebi.ac.uk/imgt/hla/stats.html). Different alleles of MICA and MICB have been reported 
to be associated with various diseases including Celiac disease, Behçet’s disease, psoriasis (Gonzalez 
et al., 1999, Stephens, 2001, Fernandez et al., 2002), Kawasaki disease and dengue fever (Garcia et 
al., 2011, Collins, 2004, Huang et al., 2000). In contrast to MHC molecules, MICs do not associate with 
 microglobulin nor do they present peptides (Eleme et al., 2004). 
The function of MIC proteins is to alert the immune system to various forms of cellular stress. 
MICA/B are upregulated on the cell surface upon different types of stress and their NKG2D-
dependent recognition leads to the activation of cytotoxic lymphocytes and the subsequent 
elimination of dangerous cells (Waldhauer and Steinle, 2008). Thus, the NKG2D/NKG2DL system 
enables the sensing of potentially dangerous conditions and the subsequent activation of immune 
cells. In this context, the expression of these molecules has to be tightly regulated. Indeed, in healthy 
adults the expression of MICA and MICB is mostly restricted to the thymic epithelium and to the 
gastrointestinal mucosa (Eagle et al., 2009). In contrast, MICA/B are up-regulated upon certain 
danger conditions including heat shock, viral infection, genotoxic stress, oxidative stress, ionizing 
radiation, histone deacetylase (HDAC) inhibitors (Kato et al., 2007), malignant transformation and 
apoptosis (Stern-Ginossar and Mandelboim, 2009). 
The molecular pathways leading to the upregulation of NKG2DL remain poorly understood. In 
general, any condition activating the major DNA damage checkpoint pathway initiated by ataxia 
teleangectasia mutated (ATM) and ATM and Rad3 related (ATR) protein kinases induces the 
transcription of NKG2D ligands (Gasser et al., 2005). Chromatin remodeling might be another 
mechanism responsible for MIC upregulation. The inhibition of histone deacetylases which switch 
DNA to its ‘open’ conformation and in this way enable the access of transcription factors to the 
MICA/B promotors results in gene activation (Zhang et al., 2009). The exact mechanisms of MICA/B 
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upregulation upon viral infection are also elusive, although chromatin remodeling has been 
functionally associated with this process (Kato et al., 2007). The transcription factors involved in 
MICA/B upregulation include ubiquitous Sp1, Sp3, NF-Y and the heat shock-induced heat shock 
transcription factor HSP-1 (Gonzalez et al., 2008, Venkataraman et al., 2007) (Fig.2). 
 
Fig.2 The regulation of NKG2D ligand transcription. NKG2D ligands expression is regulated by diverse 
mechanisms. Heat shock elements (HSE) in the promotor region of MIC respond to heat shock factor 
1 (HSF-1). Viral immediate early proteins (IE1/IE2) from Cytomegalovirus (CMV) or histone 
deacetylase Inhibitors enhance NKG2D ligand expression by inducing the remodeling of chromatin. 
The DNA damage checkpoint pathway, initiated by ATM and ATR protein kinases also induces the 
transcription of NKG2D ligands (Modified from (Lopez-Larrea et al., 2008)). 
Since genetic instability is the main characteristic of transformed cells, many types of cancer over-
express at least one of these ligands on the cell surface. However, it still remains elusive, whether 
malignant transformation itself is sufficient for MICA/B transcription (Boissel et al., 2006, Spies, 2008, 
Okita et al., 2012). MICA/B expression has been proven on many progressing tumors including 
melanomas, neuroblastomas (Pende et al., 2002) breast, lung, prostate, ovarian, renal, prostate and 
colon carcinomas (Groh et al., 1999) and also in different leukemia cell lines (Weiss-Steider et al., 
2011, Salih et al., 2003). 
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Additionally, it has been shown that toll-like receptor (TLR) signaling pathways and different 
cytokines could also affect the expression of NKG2D ligands. For example, TLR signaling triggers the 
NKG2DL expression in dendritic cells (Ebihara et al., 2007), macrophages (Hamerman et al., 2004) and 
activated T cells (Rabinovich et al., 2003); this might be a regulatory mechanism of NK cells limiting 
the function of overactivated immune cells (Eagle and Trowsdale, 2007). Induced MIC expression has 
been also documented in human cytomegalovirus (HCMV)-infected fibroblasts and endothelial cells 
(Groh et al., 2001). In response to INF- MICA was expressed on dendritic cells (Jinushi et al., 2003) 
whereas INF-and TGF- downregulated MICA expression in melanomas (Schwinn et al., 2009) and 
in gliomas, respectively (Eisele et al., 2006). 
In order to avoid unwanted damage, the expression of MICA/B has to be tightly regulated. 
Interestingly, it has been shown that different cells and tissues express NKG2DL mRNA but lack 
protein expression, suggesting regulatory mechanisms on the posttranscriptional/posttranslational 
level. Endogenous miRNAs repress their translation by binding to three prime untranslated region 
(3’UTR) of MIC and thus regulate the MICA/B expression on the posttranscriptional level (Stern-
Ginossar and Mandelboim, 2009, Nice et al., 2009). Ubiquitination might display a posttranslational 
regulatory mechanism of MICA expression. Ubiquitin ligase K5 down-regulates cell-surface 
expression of MICA by ubiquitination of the MICA cytoplasmic tail lysine residues and results in 
redistribution of MICA from the plasma membrane to an intracellular compartment, but does not 
result in an increased rate of degradation (Thomas et al., 2008).   
2.5 The role of the NKG2D system in tumor-immune interaction  
Research over the past two decades suggests a pivotal role of NKG2D system in cancer immuno-
surveillance. The interaction of the NKG2D receptor with MIC molecules expressed on different 
tumor cells elicits cytotoxic effector functions initiating the elimination of malignant cells (Fig. 3).  
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Fig.3 The role of the NKG2D system in tumor-immune interaction. Expression of NKG2D ligands on 
transformed cells facilitates recognition by NKG2D receptor-expressing NK cells, CD8+ αβ-TCR+ T cells 
and γδ-TCR+ T cells and triggers cytotoxic effector functions. (Modified from (Lanier, 2001)).  
The critical role of the NKG2D system has been shown in different model systems. In vitro, in 
melanomas and leukemia cell lines, the cytotoxic effect mediated by the NKG2DR-L interaction was 
correlated with the expression and surface density of MICA and other NKG2D ligands as well (Pende 
et al., 2002). Enhanced expression of MICA/B by sodium butyrate, a potent histone deacetylase 
inhibitor resulted in an increased susceptibility of cervical carcinoma and hepatoma cells to NK cell 
mediated lysis in an NKG2D-dependent manner (Zhang et al., 2009). In leukemia cells treatment with 
trichostatin A (histone deacetylase inhibitor) increased the cytotoxic potential of NKG2D expressing 
NK and CD8+ T cells in a MICA/B-dependent manner (Kato et al., 2007). Furthermore, a MICA-
containing bispecific antibody (MICA-CD20 fusion protein) increased the cytotoxic activity of NK cells 
against lymphoma cell lines and enhanced antibody-dependent cell-mediated cytotoxic (ADCC) 
activity of daratumumab (antineoplastic monoclonal antibody) in freshly isolated leukemias (Kellner 
et al., 2012). 
Apart from the in vitro studies described above, in vivo mice models have confirmed the critical role 
of the NKG2D system in cancer immunosurveillance as well. NKG2D-deﬁcient transgenic 
adenocarcinoma of mouse prostate models (TRAMP) appear to be defective in the control of 
spontaneous malignancies compared to wild type mice. These mice displayed early-arising, malignant 
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prostate tumors, while NKG2D-positive mice mostly developed late-arising benign tumors (Guerra et 
al., 2008). In another model, mice treated with neutralizing anti-NKG2D antibodies were more 
susceptible to methylcholantrene-induced (MCA) sarcomas than the mice treated with the isotype 
control, pointing out the important role of the NKG2D system in the control of newly arising tumors 
(Smyth et al., 2005). The importance of the NKG2D system was further confirmed in the clinic. The 
tumoricidal effect of cytokine-induced killer cells (CIK) cells (ex vivo expanded polyclonal T effector 
cells cultured under cytokine stimulation) is mostly dependent on NKG2D-mediated recognition of its 
cognate ligands, MICA and MICB on the target cells (Verneris et al., 2004). CIK immunotherapy has 
shown promising outcome in several early clinical trials in the United States (Leemhuis et al., 2005) 
and are routinely used in practice in China (Linn and Hui, 2010). So far CIK cells are the most effective 
example of an adoptive immunotherapy. 
2.6 Escape mechanisms from NKG2D system-mediated immune surveillance 
In a process referred to as “immunoediting”, tumor cells have developed several mechanisms to 
actively bypass immune surveillance mediated by the NKG2D system. Tumor cells reduce their 
immunogenicity by modulating the cell surface expression of MICA and MICB via several mechanisms 
as well as affect the expression of NKG2D by releasing suppressive cytokines (Vesely et al., 2011). 
Downregulation and degradation of NKG2D ligands and the receptor by tumor-derived cytokines: 
TGF- as the main immunosuppressive cytokine released by transformed cells downregulates MICA 
expression, simultaneously induces NKG2D receptor internalization (Castriconi et al., 2003) and thus 
interferes with NK cell-mediated cytotoxicity (Lee et al., 2004).  Consequently, the depletion of TGF- 
increases the immunogenicity of tumors and susceptibility to NK cell-mediated killing (Eisele et al., 
2006).  
Altered epigenetic profile: histone deacetylases are frequently overexpressed in cancer cells (Glozak 
and Seto, 2007). Since inhibitors of HDAC increase the expression of MIC molecules (Kato et al., 2007, 
Huang et al., 2011) alterations in epigenetic gene regulation could limit the cell surface expression of 
MICA/B and decrease the immunogenicity of transformed cells.  
Intracellular retention of NKG2D ligands: In some melanomas, MIC molecules are not expressed on 
the cell surface, but accumulate as immature forms in the endoplasmic reticulum (ER). The lack of 
surface MIC expression has been correlated with lower NK cell-mediated killing (Fuertes et al., 2008).  
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Ectodomain shedding of MICA/B: The proteolytic cleavage of NKG2DL at an extracellular site reduces 
the surface expression and releases the soluble extracellular domain and is regarded as the main 
immune escape mechanism. The amount of soluble MICA/B in the sera of cancer patients is 
significantly higher compared to healthy individuals (Salih et al., 2002) and is associated with poor 
prognosis (Holdenrieder et al., 2006). Shedding of MICA/B promotes tumor progression in various 
ways: (i) It decreases the cell surface expression of these molecules and reduces the immunogenicity 
of tumors. (ii) Soluble forms of MICA/B molecules impair the cytotoxic potential of NK cells by 
interfering with NKG2D binding sites and inducing the internalization of the NKG2D receptor on 
effector cells (Duan et al., 2011, Groh et al., 2002). (iii) Soluble MIC molecules promote the expansion 
of an immunosuppressive CD4+CD25+NKG2D+ T cell population (Groh et al., 2006). Various members 
of the metalloprotease family have been identified as inducers of MICA/B cleavage. However, most 
of the studies have been performed in MIC over-expressing systems (Boutet et al., 2009, Waldhauer 
et al., 2008, Salih et al., 2002) and the exact mechanism of the shedding of endogenous MICA and 
MICB molecules requires further investigation.   
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Fig. 4 Tumor immune evasion by cleavage of MICA/B. The ectodomain shedding of MICA/B from the 
surface of tumor cells decreases the immunogenicity of cancer cells. The soluble form of MICA/B 
interferes with the binding of NKG2D to its ligands.  
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2.7 Suspected proteases in the proteolytic cleavage of NKG2D ligands 
2.7.1 Ectodomain shedding 
Ectodomain shedding is a posttranslational mechanism that regulates the expression of cell surface 
proteins by cleavage. This cleavage usually occurs in the stalk region near the plasma membrane and 
leads to the release of the extracellular part of the protein (Arribas and Borroto, 2002). This results in 
the downregulation of cell surface expression and the generation of the soluble form of the protein, 
in many cases in a fully active form (Hooper et al., 1997).  
Targets of ectodomain shedding include transmembrane growth factors, adhesion molecules, 
membrane receptors and ligands. Hence, ectodomain shedding regulates many (patho)physiological 
processes including cell development, migration, inflammation and tumorigenesis (Garton et al., 
2006, Higashiyama et al., 2011). 
Ectodomain shedding is regulated by Erk/MAPK and p38/MAPK signaling pathways. The activation of 
these pathways by different stimuli drastically increases the basal ectodomain shedding observed in 
non-stimulated cells (Fan and Derynck, 1999).  
The major executors of ectodomain cleavage are members of the “a disintegrin and metalloproteases 
(ADAM)” (Huovila et al., 2005) and the matrix metalloproteases (MMP) family (Gialeli et al., 2011). 
However, extracellular proteolysis can also be mediated by extracellular serine, cysteine or aspartic 
proteases. Type II transmembrane serine proteases (matriptases) or tissue plasminogen activator 
(tPA) and urokinase plasminogen activator (uPA) serine proteases have been involved in extracellular 
proteolysis during metastasis and invasion (Dano et al., 2005, List et al., 2006). Cysteine proteases 
belonging to the cathepsins are localized on the cell surface during malignant transformation and 
play a role in extracellular matrix degradation (Sloane et al., 2005). The membrane-anchored aspartic 
protease, BACE, releases the -site of Amyloid Precursor Protein APP and is involved in the 
pathogenesis of Alzheimer’s disease (Yan et al., 1999). 
 2.7.2 ADAM metalloproteases 
ADAM proteases belong to the metzincins- family of zinc proteases. The metzincins include 
serralysins, astacins, matrixins, and adamalysins. ADAM family members belong to the adamylasins 
together with snake venom metalloproteinases (SVMPs) and ADAMTS (ADAMs containing 
thrombospondin motifs). Twelve ADAMs (ADAM8, 9, 10, 12, 15, 17, 19, 20, 21, 28, 30, 33) out of 40 
described ADAM family members are catalytically active. Structurally ADAMs consist of an N-terminal 
signal sequence followed by a prodomain, a metalloprotease domain, a disintegrin domain with a 
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cysteine-rich region, an EGF domain, a transmembrane domain and a cytoplasmic tail (Seals and 
Courtneidge, 2003). The interaction of a cysteine residue in the prodomain with the zinc ion in the 
catalytic site maintains the ADAMs in the inactive state and the removal of the prodomain is required 
for the activation of ADAM proteases (Anders et al., 2001). ADAMs have been implicated in diverse 
(patho)physiological processes such as cell development, cell migration, adhesion, inﬂammation, 
autoimmune disorders and most importantly in carcinogenesis (Reiss and Saftig, 2009). 
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Fig. 5 The structure and activating mechanism of ADAMs. Removal of the prodomain switches ADAM 
proteases to their active form. Activated ADAM cleaves the substrate from the cell surface and 
releases the extracellular domain of the protein.  
 
Recent evidence shows that the increased expression of individual ADAM proteases is associated 
with various types of cancer (Lu et al., 2008). In gastric cancers the upregulation of ADAM9/12/15 has 
been observed (Carl-McGrath et al., 2005) whereas in breast cancers the particular role of 
ADAM9/12/17 has been documented (Lendeckel et al., 2005). ADAMs may promote cancer 
progression by the release of stimulating growth factors such as members of the EGFR/HER family of 
ligands. By the cleavage of adhesion molecules, ADAMs increase the invasiveness and metastatic 
potential of tumors (Duffy et al., 2011).  
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2.7.3 ADAM10 and ADAM17 
 
ADAM10 and ADAM17 are the best characterized members of the ADAM family so far. The 
substrates of ADAM17/10 include growth factors and their receptors, chemokines, adhesion 
molecules and many other transmembrane proteins involved in different regulatory processes.  
 
The particular role of ADAM10 has been documented in several (patho)physiological conditions. By 
the cleavage of the Notch receptor and Delta Like Ligand-1 (DLL1), a receptor-ligand system 
controlling the cell fate in a broad range of tissues, ADAM10 plays an important role in cellular 
development (Pan and Rubin, 1997, Six et al., 2003). Moreover, ADAM10 is involved in pathogenesis 
of Alzheimer´s disease by the cleavage of APP (Allinson et al., 2004). By cleaving Fas ligand (the ligand 
of death receptor Fas) ADAM10 is an important regulator of FasL induced cell death (Schulte et al., 
2007). 
  
So far documented substrates of ADAM17 are TNF- (Black et al., 1997), TGF-, L-selectin (Peschon 
et al., 1998), TNF receptors I and II (Reddy et al., 2000, Tokumaru et al., 2000), IL-6 Receptor (Chalaris 
et al., 2007) and several other molecules involved in cell growth, inflammation, cell migration, 
carcinogenesis and adhesion (Reiss and Saftig, 2009).  
 
ADAM10 and 17 are ubiquitously expressed and upregulated in cancers (Duffy et al., 2011, Duffy et 
al., 2009). By activation of different growth-stimulating  factors (Schafer et al., 2004, Duffy et al., 
2011, Sahin et al., 2004), by shedding of adhesion proteins and thus affecting the adhesion properties 
of tumor cells (Janes et al., 2005), ADAM10/17 promote tumor progression and increase both the 
metastasic potential and the invasiveness of cancers. Moreover, recent findings indicate that 
ADAM10/17 contributes to carcinogenesis by cleaving the stress antigens MICA/MICB from the cell 
surface of tumors (Waldhauer et al., 2008, Boutet et al., 2009). Considering this ADAM10/17 might 
be strategic targets for cancer therapy.  
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3. Aim of the study 
 
The ectodomain shedding of MICA and MICB molecules from tumor cells decreases the killing 
capability of NKG2D receptor-expressing immune effectors and promotes tumor immune escape. 
However, the shedding of endogenous MICA/B molecules is not precisely defined and the better 
understanding of this cleavage machinery might be beneficial for the development of effective 
cancer therapeutic strategies.  
In this study we aimed to investigate:  
1. Expression of endogenous MICA/B molecules in different carcinoma cell lines. We aimed to 
analyze different carcinoma cell lines for the baseline and PMA-induced expression of endogenous 
MICA/B molecules. 
2. Ectodomain shedding of endogenous MICA/B molecules. With inhibitory studies and siRNA-
mediated targeting of individual proteases, we aimed to define the proteases responsible for the 
shedding of endogenously expressed MICA and MICB molecules.  
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4. Materials 
4.1 Cell biology 
4.1.1 Cell lines 
Panc89 
 
Pancreas ductal adenocarcinoma 
 
Institute for Experimental Cancer Research, 
Kiel, GER 
PancTu-I 
 
Pancreas ductal adenocarcinoma 
 
Institute for Experimental Cancer Research, 
Kiel, GER 
PC-3 Prostate adenocarcinoma ATCC, USA 
MDA-MB-231 Breast adenocarcinoma ATCC, USA 
4.1.2 Reagents, buffers and media used for cell culture 
RPMI-1640 medium (25 mM HEPES, L-glutamine) Invitrogen, Carlsbad, USA 
FCS (heat-inactivated and sterilized by filtration) Invitrogen, Carlsbad, USA 
Penicillin/streptomycin (1 x 104 U/1 x 104 µg/ml) Biochrom AG, Berlin, GER 
Trypsin-EDTA (0,05%/0,02% (w/v)) Biochrom AG, Berlin, GER 
PBS w/o Ca2+/Mg2+ Cell Concept, Freiburg, GER 
 
4.1.3 Materials used in flow cytometry 
Buffers and reagents  
  
FACS washing buffer 
1x PBS Biochrom AG, Berlin, GER 
1% (w/v) BSA Carl Roth, Karlsruhe, GER 
0.1% (w/v) NaN3 Merck KGaA, Darmstadt, GER 
 
  
Fixation buffer   
1% (w/v) PFA (in PBS) Merck KGaA, Darmstadt, GER 
Inhibitor  Specificity 
Used 
Concentration Source 
GM6001 (in DMSO) Metalloproteases 5 µM Calbiochem, GER 
TAPI-I (in DMSO) Metalloproteases 5 µM Calbiochem, GER 
AEBSF Hydrochloride (in H2O) Serine proteases 25-100 µM Calbiochem, GER 
Leupeptin (in H2O) Cystein/serine Proteases 100 µM Calbiochem, GER 
Pepstatin A(in DMSO) Aspartate Proteases 10 µM Calbiochem, GER 
Cycloheximide Inhibitor of protein syntesis 0.033-0.15 µg/ml Calbiochem, GER 
    
Stimulator        
Phorbol 12-Myristate-13-Acetate (PMA)  50-100 ng/ml Sigma, GER 
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BD Cytofix/Cytoperm Fixation/Permeabilization Kit 
Kit Components  (BD Biosciences, USA)  
Fixation/Permeabilization solution (125 ml)  
BD Perm/Wash buffer 10x  
(diluted 1:10 prior to use in distilled water) 
  
FcR blocking reagent  Miltenyi Biotec, USA 
diluted 1:10 prior to use in FACS buffer 
 
4.1.4 Materials used in enzyme-linked immunosorbent assay (ELISA) 
 
 
 
 
 
 
 
 
 
Antibodies used for cell surface staining     
Specificity Clone # 
Used 
Concentration Species  Isotype  Source    
Isotype control-PE 133303 25 µg/ml mouse IgG2b R&D Systems, USA 
Anti-human MICA-PE 159227 25 µg/ml mouse IgG2b R&D Systems, USA 
Anti-human MICB-PE 236511 25 µg/ml mouse IgG2b R&D Systems, USA 
Isotype control-PE x40 25 µg/ml mouse IgG1 BD Biosciences, USA 
Anti-human NKG2D-PE 149810 25 µg/ml mouse IgG1 R&D Systems, USA 
Anti-human ADAM17-PE 111633 25 µg/ml mouse IgG1 R&D Systems, USA 
       
Antibodies used for intracellular (IC) staining      
Specificity Clone # 
Used 
Concentration Species  Isotype  Source    
Isotype control-PE (IC) G155178 0,25 µg/ml mouse IgG2a BD Pharmingen 
Anti-human ADAM10-PE (IC) 163003 0,25 µg/ml mouse IgG2b R&D Systems, USA 
Buffers and reagents  
Reagent Diluent (RD) 
1x PBS Biochrom AG, Berlin, GER 
1% (w/v) BSA Carl Roth, Karlsruhe, GER 
ELISA washing buffer 
1x PBS Biochrom AG, Berlin, GER 
0,05% (v/v) Tween-20 Merck KGaA, Darmstadt, GER 
Substrate Reagent Pack R&D Systems, USA (#DY999) 
Color Reagent A Stabilized hydrogen peroxide 
Color Reagent B Stabilized tetramethylbenzidine 
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4.2 Molecular biology 
4.2.1 Small interfering RNAs used for gene silencing 
Stealth  RNA   Invitrogen, Carlsbad, USA  
Final 
Concentration 
ADAM10 stealth RNA Sense GGUGUUGCUGAGAGUGUUAAUUCU 25 nM 
 Antisense AGAAUUAACACUCUCAGCAACACCA 
ADAM17 stealth RNA Sense CCAGGGAGGGAAAUAUGUCAUGUAU 25 nM 
 Antisense AUACAUGACAUAUUUCCCUCCCUGG 
Stealth control RNAi Negative Control Med GC Duplex 25 nM 
      
Lipofectamine RNAiMAX Invitrogen, Carlsbad, USA 1,67 µL/ml 
Opti-MEM Reduced Serum Medium Invitrogen, Carlsbad, USA  
 
4.2.2 Materials used for the isolation of genomic DNA      
Materials provided in genomic DNA purification kit     (MACHEREY-NAGEL, GER) 
Lysis Buffer BQ1 
Washing Buffer BQ2 
Elution Buffer BE 
Lyophilized Proteinase K, dissolved in PB buffer 
NucleoSpin®Blood Columns 
Collection Tubes 
 
 
 
Materials provided in human MICA ELISA duo set kit  
R&D Systems, USA (#DY1300)  Dilution 
Capture Antibody 360 µg/ml in PBS 1:180 in PBS 
Detection Antibody 72 µg/ml in RD 1:180 in RD 
Standard MICA 180 µg/ml in RD  1:45 in RD 
Streptavidin-HRP 1ml   1:200 in RD 
Materials provided in human MICB ELISA duo set kit 
R&D Systems, USA (#1599) Dilution 
Capture Antibody 720 µg/ml in PBS 1:180 in PBS 
Detection Antibody 72 µg/ml in RD 1:180 in RD 
Standard MICA 370 µg/ml in RD  1:37 in RD 
Streptavidin-HRP 1ml 1:200 in RD 
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4.3 Protein biochemistry 
 
4.3.1 Cell lysis buffers and reagents  
TNE lysis buffer   
1% (v/v) NP-40 Fluka Riedel-de Häen/Sigma, GER   
50 mMTris Merck KGaA, Darmstadt, GER   
150 mM NaCl Merck KGaA, Darmstadt, GER   
2 mM EDTA Merck KGaA, Darmstadt, GER  
 
NP-40 lysis buffer   
1% (v/v) NP-40 Fluka Riedel-de Häen/Sigma, GER   
20 mM Tris Merck KGaA, Darmstadt, GER   
150 mM NaCl Merck KGaA, Darmstadt, GER   
   
 
 
 
 
 
 
 
 
 
 
4.3.2 Materials used for immunoprecipitation 
Materials used in immunoprecipitation and deglycosylation 
  
Protein G sepharose™ 4B beads Zytomed, Munich, GER 
G7 reaction buffer 10x New England BioLabs, UK  
PNGaseF 500.000 U/ml New England BioLabs, UK 
10% NP-40 New England BioLabs, UK 
Denaturing buffer 10x New England BioLabs, UK 
 
RIPA buffer:  
20 mM Tris-HCl (pH 7.5)  Merck KGaA, Darmstadt, GER 
150 mM NaCl, 1 mM Na2EDTA Merck KGaA, Darmstadt, GER 
1 mM EGTA Merck KGaA, Darmstadt, GER 
1% NP-40 Fluka Riedel-de Häen/Sigma, GER 
1% sodium deoxycholate  
2.5 mM sodium pyrophosphate    
1 mM -glycerophosphate  
Inhibitors cocktail: (1:100) Sigma-Aldrich, St. Luis, USA 
104 mM AEBSF 1.4 mM E-64 
80 µM Aprotinin 2 mM Leupeptin 
4 mM Bestatin 1.5 mM pepstatin A 
Bradford Reagent Thermo Scientific, Karlsruhe, GER 
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4.3.3 Materials used for SDS-page   
4.3.3.1 NuPAGE system mini gels (Invitrogen) 
Buffers and reagents used in mini gels 
 
2x SDS sample buffer 
125 mM Tris Merck KGaA, Darmstadt, GER 
4% (w/v) SDS Merck KGaA, Darmstadt, GER 
20% (v/v) glycerol Merck KGaA, Darmstadt, GER 
0.005% (w/v) bromophenol blue Merck KGaA, Darmstadt, GER 
10% (v/v) -2-mercaptoethanol Merck KGaA, Darmstadt, GER 
 
10x Running buffer 
30 g/l Tris Merck KGaA, Darmstadt, GER 
144 g/l glycine Carl Roth, Karlsruhe, GER 
10 g/l SDS Merck KGaA, Darmstadt, GER 
 
Prestained high-range Standard Bio-Rad, Hercules, USA 
Prestained low-range Standard Bio-Rad, Hercules, USA 
4.3.3.2 Protean II system gels (Bio Rad)  
Materials for Protean II system gels 
    
Running gel (Protean II system, 10%, 30 ml) 
10.0 ml 30% acrylamide/0.8% bisacrylamide Carl Roth, Karlsruhe, GER 
11.2 ml 1 M Tris, pH 8.8  Merck KGaA, Darmstadt, GER 
0.3 ml 10% (w/v) SDS  Merck KGaA, Darmstadt, GER 
8.7 ml aqua ad iniectabilia  Braun, Melsungen, GER 
0.1 ml 20% APS   Merck KGaA, Darmstadt, GER 
0.02 ml TEMED   Carl Roth, Karlsruhe, GER 
       
Stacking gel (Protean II system, 10 ml) 
1.67 ml 30% acrylamide/0.8% bisacrylamide Carl Roth, Karlsruhe, GER 
1.25 ml 1 M Tris, pH 6.8  Merck KGaA, Darmstadt, GER 
0.1 ml 10% (w/v) SDS  Merck KGaA, Darmstadt, GER 
7.0 ml aqua ad iniectabilia  Braun, Melsungen, GER 
0.05 ml 20% APS   Merck KGaA, Darmstadt, GER 
0.01 ml TEMED   Carl Roth, Karlsruhe, GER 
 
 
 
3x reducing sample buffer (Protean II system) Bio-Rad, Hercules, USA 
Precision Plus Protein All Blue Standard Bio-Rad, Hercules, USA 
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4.3.4 Materials used for western blotting and IP 
Antibodies  in WB and IP  Clone# Concentration Dilution Species  Source  
Anti-human ADAM10 (WB) Polyclonal 1 mg/ml 1/1000 Rabbit Millipore, GER 
Anti-human ADAM17 (WB) Polyclonal 1 mg/ml 1/1000 Rabbit Millipore, GER 
Anti-human MICA/B (WB) 
 BAMO1 1 mg/ml 1/1000 
mouse 
IgG1 BAMOMAB, GER 
Anti-human MICA (IP) 
 159227 360 µg/ml 1ug/ml 
mouse 
IgG2b R&D Systems, USA 
Anti- actin(WB) 
 AC-15 2,9 mg/ml 1/10000 
mouse 
IgG1 Sigma, GER 
      
HRP-conjugated antibodies Dilution Species  Source  
Anti-rabbit IgG-HRP  1/10000 donkey GE Healthcare,UK 
Anti-rabbit IgG-HRP  1/10000 donkey GE Healthcare,UK 
 
Buffers and reagents used in western blotting 
Washing buffer (TBS-T) 
Tris 10 mM Merck KGaA, Darmstadt, GER 
NaCl 150 mM Merck KGaA, Darmstadt, GER 
Tween 20 0,05% (v/v) Merck KGaA, Darmstadt, GER 
 
 
 
 
 
 
 
 
 
 
 
 
Transfer buffer    
25 mM Tris Merck KGaA, Darmstadt, GER 
192 mM glycine Carl Roth, Karlsruhe, GER 
20% (v/v) methanol Sigma-Aldrich, St. Louis, USA 
0.015% (w/v) SDS Merck KGaA, Darmstadt, GER 
  
Blocking buffer  
5% (w/v) BSA in TBS-T Serva Electrophoresis GmbH, GER 
5% (w/v) Dry Milk in TBS-T  Granovita, GER 
Ponceau S staining solution Sigma-Aldrich, St. Luis, USA 
ECL™  detection reagents 
 
GE Healthcare, UK 
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4.4 Consumables 
 
Laboratory consumables 
Centrifuge tubes (15ml, 50ml) Greiner, Kremsmünster, AUT 
Reaction tubes (1.5 ml, 2.0 ml) Sarstedt AG, Nümbrecht, GER 
Pipette (filter) tips Sarstedt AG, Nümbrecht, GER 
  Greiner, Kremsmünster, AUT 
  Biozym, Hessisch Oldendorf, GER 
Cryotubes Nunc, Roskilde, DEN 
Cell culture flasks Greiner, Kremsmünster, AUT 
FACS tubes Dunn, Asbach GER 
96-well plates Nerbe, Winsen, GER 
  Nunc, Roskilde, DEN 
24-, 6-well plates Greiner, Kremsmünster, AUT 
   
NuPAGE™ 4-12% Bis-Tris gels (1.5 mm) Invitrogen, Carlsbad, USA 
Nitrocellulose membrane Hybond™ C (0.4 μm) GE Healthcare, UK 
Amersham Hyperfilm ECL™ GE Healthcare, UK 
4.5 Laboratory equipment 
 
CO2-humified, water jacketed incubator Forma Scientific, Marietta, USA 
Flow cytometer FACSCalibur BD, East Rutherford, USA 
Microplates-Photometer reader  'infiniteTM M200'  Tecan, Crailsheim, GER 
Development machine Curix60 Agfa, Mortsel, Belgium 
NanoDrop™ ND-1000 Thermo Scientific, USA 
SmartSpec™3000 spectrophotometer Bio-Rad, Hercules, USA 
Protean® II electrophoresis chamber Bio-Rad, Hercules, USA 
Transfer-Tank (Mini) Trans-Blot® Bio-Rad, Hercules, USA 
Film cassettes Amersham/GE Healthcare, UK 
Inverse light microscopes Carl Zeiss, Jena, GER 
Neubauer hemocytometer Fischer, Frankfurt, GER 
Megafuge 10 Heraeus, Osterrode, GER 
Biofuge 15R Heraeus, Osterrode, GER 
Shaking water bath GFL, Burgwedel, GER 
Rocking device Fröbel, Lindau, GER 
Vortex-Genie 2 Scientific Industries, USA 
Calibrated densitometric gel scanner GS-800 Bio-Rad, Hercules, USA 
Pipetting aid accu-jet pro Brand, Wertheim, GER 
Pipettes Eppendorf, Hamburg, GER 
 Gilson, Middleton, USA 
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5. Methods 
5.1 Cell biology 
5.1.1 Cell culture 
The pancreas ductal adenocarcinomas Panc89 and PancTu-I and the breast cancer cell line MDA-MB-
231 were cultivated in RPMI-1640 growth medium. The prostate cancer cell line PC-3 was cultured in 
F-12K medium. The growth media were supplemented with 10% heat inactivated Fetal Calf Serum 
(FCS), 100 U/ml Penicillin and 100 µg/ml Streptomycin. All cell lines were cultivated at 37°C in a 
humidified atmosphere with 5% CO2.  
For passaging the adherent cells (Panc89 and PancTu-I, MDA-MB-231 and PC-3) cells were detached 
by sterile Trypsin/EDTA (0,05%/0,02%) and centrifugated at 300 g for 5 minutes. Cells were seeded 
in fresh medium at a density to reach 80-90% confluence within 48-72 hours. 
In inhibitor studies, fixed numbers of cells were treated with non-toxic concentrations of inhibitors 
and with PMA where indicated. After 24 hours of cultivation, the conditioned medium and cellular 
lysates were subjected to ELISA.  
5.1.2 Flow cytometry  
Flow cytometry is a method for the identification and quantification of cellular antigens. The main 
principle of flow cytometry is to measure the light,emitted by the cell as it passes through a focused 
laser beam. Cells coated with specific, fluorochrome-conjugated antibodies are excited by the laser 
and the specific emission light correlates with amount of antigen. The data provides information 
about the granularity and size of the cell and about the expression of a given protein (Murphy et al, 
2008). 
To determine the cell surface expression of MICA, MICB and ADAM17 1 x 105 cells were transferred 
to 96-well plates and washed twice (centrifugation at 300g, 4°C, 4 min) with 180 µL FACS washing 
buffer. Samples were blocked with 20 µL Fc receptor blocking reagent for 15 minutes at 4°C in the 
dark. Following another washing step, cells were incubated for 30 minutes with either 10 µL of 
phycoerythrin (PE)-conjugated specific antibodies or with the appropriate isotype control at 4°C. 
Afterwards, cells were washed twice and fixed in 1% PFA. 
For intracellular staining of ADAM10, the commercially available Cytofix/Cytoperm 
Fiaxtion/Permeabilization Kit was used (BD Biosciences, USA). Following the FcR blocking step, cells 
were resuspended in 100 µL Fixation/Permeabilization solution for 20 minutes at 4°C and washed 
with Perm/wash buffer two times. Fixed and permeabilezed cells were stained (30 min, 4°C, in the 
dark) with 100 µL of PE-conjugated antibody detecting the intracellular part of ADAM10 and with the 
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corresponding isotype control. Following two washing steps with Perm/wash buffer, cells were 
resuspended in 1% PFA. 
5000 living cells of each sample were measured with the FACS Calibur Flow Cytometer and analysed 
using CellQuest Pro software (BD Biosciences, USA).  
5.1.3 Enzyme-linked immunosorbent assay (ELISA) 
An enzyme-linked immunosorbent assay (ELISA) is a sensitive immunological technique specifically 
detecting an antigen and determining its concentration in liquid samples. The main principle of this 
approach is to detect the target molecule via specific enzyme-coupled antibodies. The antigen-
antibody interaction causes the conversion of a substrate into a colored, detectable product. Light 
absorbance is detected by an ELISA Reader. The intensity of the signal is directly proportional to the 
amount of antigen captured in the plate by binding to the detection reagent (Engvall and Perlmann, 
1971). 
The amount of soluble and cellular MICA/B was determined by commercially available MICA and 
MICB Elisa kits (Human Duo set MICA and MICB, R&D Systems, USA) following manufacturer’s 
instructions. Briefly, 96-well ELISA plates were coated with 100 µL of capture antibody overnight. 
After three washes with 400 µl ELISA washing buffer the wells were blocked with 300 µL of diluent 
reagent and incubated for 1 hour at room temperature. Following three further washing steps 100 
µL conditioned medium and cellular lysates (prepared as described in 5.3.1.1 and previously diluted 
in diluent reagent) were added in duplicates and incubated for two hours. Serial dilutions of 
recombinant MICA/B served as a standard. Bound MICA/B was detected using 100 µl of a 
biotinylated detection antibody (2 h) followed by incubation with   100uL of HRP-conjugated 
streptavidin for 30 minutes. Afterwards 100 µL of a substrate solution (equal mixture of color 
reagents A and B) were added to each well and the color reaction was stopped after 8-10 minutes by 
adding 50 µL of 2N sulfuric acid. The absorbance was measured at 450 nm against 570 nm reference 
wavelength with the Infinite@200PRO Elisa Reader (Tecan, USA). 
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5.2 Molecular biology 
5.2.1 Gene silencing by RNA interference 
 
SiRNA interference is a widely used approach for the specific silencing of a given protein of interest. 
Small double stranded RNAs 21-23 base pairs in length; integrates in the RNA-induced silencing 
complex (RISC) and induce the degradation of specific mRNAs with complementary sequence. For 
the effective transfection, commercially available transfection reagents (Lipofectamine RNAiMAX, 
Invitrogen) are commonly used. 
To induce ADAM10 and ADAM17 gene silencing, specific and control synthetic siRNA duplexes 
(Invitrogen, USA) were mixed with lipofectamine RNAiMAX (diluted in 50 µl Opti-MEM serum-
reduced medium prior to use). Following incubation for 20 minutes at RT in the dark, the mixture 
was added to 70.000 cells suspended in 500 µl of medium and was seeded in 24-well plates and 
incubated for 72 hours at 37°C. Medium was replenished and the protein knockdown efficiency was 
confirmed by Western Blot and flow cytometry. Cells were incubated for further 24 h and the the 
conditioned media was subjected to ELISA.  
5.2.2 Isolation of genomic DNA  
For the genotyping of MICA, genomic DNA was isolated with the Genomic DNA Purification kit 
(MACHEREY-NAGEL, GER). 2 x 105 cells were resuspended in 200 µl PBS and mixed with 25 µl 
proteinase K and 200 µl BQ1 lysis buffer. Following incubation at 70°C for ten minutes, 200 µl pure 
ethanol was added and vigorously vortexed. Afterwards the samples were loaded to 
Nucleospin®Blood Quickpure Columns. After centrifugation at 11.000 g for one minute, Nucleospin® 
Blood Columns were washed twice with Washing Buffer BQ2 (350 and 200 µl, respectively). Genomic 
DNA was eluted by the addition of 50 µl prewarmed elution buffer BE followed by incubation at 
room temperature for one minute and centrifugation at 11.000 g for one minute. Samples were 
analyzed at the Institute of Clinical Transfusion Medicine and Immunogenetics, in Ulm, Germany 
(Furst et al., 2011).  
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5.3 Protein biochemistry 
5.3.1 Preparation of cellular lysates 
Cells were harvested and washed with PBS at 300 g, for 5 min. Lysis buffer supplemented with 
inhibitor cocktail was added to the pellet and the sample was incubated on ice for 40 min. Lysates 
were subjected to centrifugation at 14.000 rpm for 10 min to remove cellular debris and subjected to 
Bradford assay for protein content determination. 
5.3.2 Bradford-assay 
 
Protein content in cellular lysates was determined by a colorimetric Bradford assay which is based 
on an absorbance shift of the dye Coomassie Brilliant Blue G-250 once bound to protein. 5 µl of the 
sample were mixed with 995 µL of Bradford reagent and incubated at RT for 10 Min. The absorbance 
was measured at 595 nm with the SmartSpec 3000 (BioRad, USA). 
 
5.3.3 Immunoprecipitation (IP) 
 
Immunoprecipitation (IP) is a widely used approach for the isolation of specific proteins from protein 
mixtures. A specific antibody binds to a target protein and the antibody-bound protein is 
immunoprecipitated by Protein G or Protein A beads. 
Cellular lysates were mixed with 1 µg of the precipitating antibody and 60 µl of protein G beads (1/1 
in lysis buffer NP-40). This mixture was incubated on a rotating device at 4°C overnight. Beads were 
sedimented by quick spin and washed three times with NP-40 lysis buffer. Beads were resuspended 
in 15 µl of sterile water and incubated with 5 µl of 10x glycoprotein denaturing buffer at 100°C for 10 
minute. Following denaturation, samples were subjected to deglycosylation by the addition of 5 µl 
sterile water, 7 µl G7 10x reaction buffer, 7 µl of 10% NP-40 buffer and 1 µl of PNGase F. Samples 
were incubated at 37°C for 1 hour. Following that samples were incubated at 100°C for 5 minutes in 
30 µl of reducing sample buffer and afterwards subjected to SDS-PAGE.  
 
5.3.4 SDS-PAGE 
 
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) is a widely used technique 
for the separation of proteins based on their size. Proteins are denaturated by the anionic detergent 
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SDS and separated by gel electrophoresis. Subsequent Western blotting enables the detection of 
target proteins by specific antibodies.  
In this study proteins were separated either by discontinuous gel electrophoresis according to 
Laemmli (Laemmli, 1970) using the Protean II system (Bio-Rad Laboratories, Hercules, USA) or by 
continuous electrophoresis with pre-cast Bis-Tris NuPAGE® gels (Invitrogen, Carlsbad, USA).  
5.3.4.1 NuPAGE system mini gels (Invitrogen) 
 
4x SDS sample buffer was added to 20 µg of total protein. Following a denaturation step at 70°C for 
10 min, samples and prestained standards marker were loaded on 4-12% acrylamide gradient Bis-
Tris gels and electrophoresis was performed in running buffer at 200 V for 45-60 minutes. 
 
5.3.4.2 Protean II system gels (Bio Rad)  
 
30 µl of reducing sample buffer were added to the precipitates and incubated at 100°C for 5 
minutes. Samples and precision plus protein marker were loaded on protean II system gels, 
composed of running and stacking gel prepared according to the method of Laemmli (Laemmli, 
1970). Electrophoresis was performed for 2 hours at 180 V and afterwards at 55 V overnight.  
 
5.3.5 Western blotting 
 
Proteins separated by SDS-PAGE were transferred to nitrocellulose membranes 0.4 µm by tank 
blotting. For Protean II system gels, this was performed in Trans-Blot® tanks at 4°C and 0.8 A for two 
hours. In the case of NuPAGE mini-gels, Mini Trans-Blot® tanks were used and the transfer was 
performed for 2h at 110 V. Transfer efficiency was documented by reversible Ponceau S staining. 
Blots were washed with TBS for 5 minutes to remove Ponceau S and afterwards blocked at room 
temperature for 1 h with 5% (w/v) BSA in TBS-T or with 5% milk in TBS-T. Blots were washed tree 
times with TBS-T and incubated with the primary antibody diluted in TBS-T or in 2% BSA (w/v) in TBS-
T for 1 h at RT or at 4°C overnight. After three to four washing steps, HRP-conjugated secondary 
antibodies diluted in TBS-T were added and incubated at room temperature for 1 h. Blots were 
washed again extensively with TBS-T and ECL solution (equal volume of the detection reagent 1 and 
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the detection reagent 2) was added for 1 min. ECL films were then exposed for an appropriate time 
in the dark and developed with the imaging device, CP1000-AGFA, GER. 
 
5.4 Statistical analysis 
 
For statistical analysis the paired, two-tailed student’s t-Test was performed. Statistical significance 
was set at p < 0.05 and displayed as  ***p<0.001 **p<0.01 *p<0.05. 
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6. Results 
6.1 Differential expression and shedding profiles of endogenous MICA and MICB molecules in 
various epithelial cancer cell lines 
Initially the expression levels and shedding profiles of endogenous MICA and MICB were determined 
in different human carcinoma cell lines. This analysis encompassed several epithelial cancer cell lines 
including the pancreatic carcinoma cell lines Panc89 and PancTu-I, the mammary carcinoma cell line 
MDA-MB-231 and the prostate carcinoma cell line PC-3. Flow cytometric analysis revealed that both 
MICA and MICB molecules are expressed on the cell surface of all analyzed cell lines, although the 
expression level of these molecules notably varied (Fig.1, A). In general, MICA expression was more 
pronounced than the expression of MICB. Only in the prostate cancer cell line PC-3 MICB was more 
abundant than MICA. In the mammary cancer cell line MDA-MB-231 and in the pancreas cancer cell 
line PancTu-I MICB expression was very low.  
 
In parallel, conditioned medium and cellular lysates were subjected to ELISA and examined for the 
level of MICA/B (Fig.1, B). The overall expression of MICA/B was also determined by ELISA of cellular 
lysates to allow for the assessment of the relative shedding. Consistent with the flow cytometry data, 
expression levels of MICA as detected from cellular lysates were higher than of MICB ranging 
between 2845 pg/ml and 843 pg/ml for MICA and 1034 pg/ml and 509 pg/ml for MICB, respectively. 
The pancreatic cancer cell line Panc89 contained the highest amount of MICA in the cellular lysates 
(2845 pg/ml), whereas the mammary cancer cell line MDA-MB-231 released the uppermost amount 
of MICA (752 pg/ml) into the supernatant. Interestingly, the prostate cancer cell line PC-3 failed to 
secrete MICA, despite the fact that it expresses both NKG2D ligands on the cell surface. However, the 
release of the highest amount of MICB (1977 pg/ml) was observed from this particular PC-3 cell line. 
The lowest release of MICB has been observed from PancTu-1 cell line. Additionally, MICA protein 
was immunoprecipitated from cellular lysates. Following deglycosylation by PNGaseF, MICA was 
detected by western blotting (Fig.1, C) as a 42 kD protein as described previously (Bahram et al., 
1994). However, in PC-3 cells MICA migrated at 33 kD. 
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Fig.1 Epithelial cancer cell lines express and release soluble MICA and MICB into the supernatant.  
Pancreatic cancer cell lines Panc89 and PancTu-I, the mammary cancer cell line MDA-MB-231 and the 
prostate cancer cell line PC-3 were cultivated for 24 hours. (A) Cell surface expression of MICA (solid 
lines) and MICB (dotted lines) was determined by flow cytometry. Shaded peaks represent the 
Isotype control. (B) Harvested supernatants (white) and cell lysates (grey) were analyzed for the 
amount of MICA (left) and MICB (right) by ELISA. The data shown are mean of three different 
experiments with +/-SEM. (C) From cellular lysates immunoprecipitated and deglycosylated MICA 
was separated in SDS-PAGE and detected in western blot.  
 
 In summary all examined cancer cell lines express MICA and MICB and display it on the cellular 
surface. Moreover, soluble MICA and MICB are released into the supernatant. However, despite the 
expression of MICA, PC-3 cells do not secrete this protein.  
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6.2 Aspartate, cysteine and serine proteases do not affect the proteolytic cleavage of MICA and 
MICB 
 
The observation that all analyzed cell lines express and release NKG2D ligands into the conditioned 
media, indicated that proteolytic cleavage within an extracellular site might release a soluble 
ectodomain of MICA/B. In order to define the proteases responsible for this process referred to as 
shedding, selected broad-band inhibitors for individual protease families were used. Panc89, PancTu-
1, PC-3 and MDA-MB-231 cells were incubated with or without inhibitors targeting aspartate 
(Pepstatin), cysteine (Leupeptin) and serine (AEBSF) proteases at non-toxic concentrations. After 24 
hours of incubation, the levels of released soluble MIC molecules in the conditioned medium were 
determined by ELISA. 
 
Fig.2 Aspartate, cysteine and serine proteases do not cause the release of MICA and MICB. Cells 
were treated for 24 hours with Leupeptin (100 µM), inhibitor of cysteine proteases, with Pepstatin 
(10 µM in DMSO) for inhibition of aspartate proteases and with AEBSF (25-50 µM) for serine 
proteases. Medium and DMSO (0.02%) served as a control. (A) Harvested supernatants were 
analyzed for the amount of MICA (left) and MICB (right) by ELISA. The value of control sample was set 
to 100%. The data shown are the mean of 3-4 different experiments with +/-SEM.   
 
The results showed that none of these inhibitors affected the proteolytic cleavage of endogenous 
MICA and MICB molecules (Fig.2). Only the serine protease inhibitor AEBSF slightly reduced the 
amount of MICB detected in the conditioned medium of PancTu-I cells. Of note, PancTu-I cells 
released the lowest amount of MICB in the supernatant.  
Thus, aspartate, cysteine and serine proteases are not responsible for the shedding of endogenous 
MICA and MICB molecules from the examined cell lines. 
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6.3 Metalloproteases are responsible for the basal and relative shedding of MICA and MICB 
 
Since members of the aspartate, cysteine and serine protease families do not account for the release 
of MICA/B, we investigated the role of metalloproteases employing a combination of the broad range 
inhibitors GM6001 and TAPI-I. Cells were incubated in the presence or absence of inhibitors at non-
toxic concentrations for 24 hours. The absolute shedding of MICA/B was assessed by the analysis of 
the harvested supernatant by ELISA. For the determination of relative shedding, the amount of the 
protein released into conditioned medium was divided by the amount detected in cellular lysates. 
The MICA/B concentration determined in untreated control samples was defined as 100%. In parallel, 
the modulation of cell surface expression was analyzed by flow cytometry. The results demonstrate 
that the treatment with GM6001/TAPI-1 dramatically decreased the shedding of MICA/B molecules 
and accordingly increased the cell surface (Fig.3) expression.  
Inhibition of metalloproteases significantly decreased the shedding of MICA and MICB. In line with 
these results, the cell surface expression of MICA was upregulated on the cell surface of Panc89, 
PancTu-I and MDA-MB-231 cells. Again, PC-3 cells expressed MICA, but in accordance with the 
observation that they do not release MICA, the cell surface expression of this molecule was not 
affected by inhibitors of metalloproteases. Despite the fact that inhibition of metalloproteases 
significantly inhibited the release of MICB, surface expression was hardly modulated in PancTu-I and 
MDA-MB-231 cells. However, in Panc89 and PC-3 cells MICB surface expression was increased 
following the inhibition of metalloproteases.  
These results imply that metalloproteases mediate the shedding of endogenous MICA/B molecules 
from human tumor cells. 
 
 36 
 
 
Fig.3 The inhibition of metalloproteases reduces the MICA and MICB release into supernatant and 
modulates their cell surface expression. Cells were treated with broad range inhibitors for 
metalloproteases GM6001 (5 µM) and TAPI-1 (5 µM) and with DMSO as a control (>0,1%) for 24 
hours. (A) Cell surface expression of MICB is determined by flow cytometry after GM6001/TAPI-1 
(dotted lines) and DMSO (solid lines) treatment. Shaded peaks represent the Isotype control. (B) The 
supernatants and cell lysates of DMSO treated samples (grey) and GM6001/TAPI-1 treated samples 
(dark grey) are analyzed for the amount of MICA/B by ELISA. To determine the absolute shedding 
activity (left), the amount of soluble protein in supernatant was measured by ELISA. For the 
calculation of the "Relative shedding" activity (right), the amount of MICA/B (pg/ml) detected in 
conditioned medium was divided by the amount of MICA/B (pg/ml) detected in cell lysates. The value 
of DMSO control is set to 100%; the data shown are the mean of three to four different experiments 
with +/-SEM. For statistical analysis 2-tail t-test is performed. ***p<0.001 **p<0.01 *p<0.05  
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6.4 Metalloproteases are the cause of phorbolester-induced shedding of MICA and MICB 
 
In a next step, we aimed to define the role of metalloproteases in the induced shedding of MICA and 
MICB. For the induction of shedding we used Phorbol 12-myristate 13-acetate (PMA), a well-known 
stimulator of metalloprotease-mediated shedding (Arribas et al., 1996).  
 
To analyze the PMA-induced release of MICA/B, cells were treated with PMA in the presence or 
absence of the metalloproteases inhibitors GM6001/TAPI-1. Conditioned media were analyzed by 
ELISA for the released amount of MICA/B and in parallel cell surface expression were determined by 
flow cytometry. PMA significantly stimulated the shedding of MICA/B (Fig.4 B). In the case of MDA-
MB-231 and PancTu-I cells shedding of MICB was not significantly increased (Fig.4 B) even when 
using higher concentrations of PMA (100 ng/ml instead of 50 ng/ml). Besides the induction of 
shedding, PMA differentially modulated the cell surface expression of the MICA/B molecules. In 
Panc89 and PancTu-I cells the surface expression of MICA as well MICB (Fig.4 A) was increased (solid 
black line), whereas it was reduced in MDA-MB-231 and PC-3 cells following PMA stimulation. As 
PMA might modulate MICA/B biosynthesis, cellular lysates were subjected to ELISA as well (Fig.5). In 
line with the results from the cell surface staining, analysis of cellular lysates by ELISA revealed that in 
the pancreas carcinoma cell lines PMA stimulation increased the overall expression of MIC molecules. 
In MDA-MB-231 and in PC-3 cells, the level of MIC molecules was reduced as a result of the induction 
of proteolytic cleavage. To further investigate the effect of PMA on MICA/B expression, 
cycloheximide, an inhibitor of protein synthesis, was used (Baliga et al., 1969). Cycloheximide was 
able to abolish this effect of PMA on the pancreas cancer (Panc89) cell line (Fig.6), indicating that 
PMA in Panc89 cells induces the synthesis of MICA/B.  
Taken together, the inhibition of metalloproteases also reduced the PMA-induced shedding of 
endogenous MIC molecules and accordingly increased the level of MICA/B surface expression. Again, 
the induced expression of MICB was hardly modulated by the metalloproteases inhibition in the case 
of MDA-MB-231 and PancTu-I cells. These results indicate that metalloproteases are responsible for 
the stimulated shedding of MICA/B.  
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Fig.4 PMA induced shedding is inhibited by the broad range inhibitors of metalloproteases. In order 
to determine the role of metalloproteases in the stimulated shedding of MICA/B, carcinoma cell lines 
were treated with 50 ng/ml (Panc89 and PC-3) and 100 ng/ml (MDA-MB-231 and PancTu-I) PMA for 
24 hours in the presence or absence of the metalloprotease inhibitors GM6001/TAPI-1. (A) 
Modulation of cell surface expression of MICA/B in control (thin solid line), in PMA- (thick solid line) 
and PMA/GM6001/TAPI-1-treated (dotted line) samples was analyzed by flow cytometry. Closed 
peaks represent the Isotype control. (B) Released amount of MICA/B was detected in the conditioned 
medium by ELISA. Data shown are the mean of 3 different experiments +/-SEM. For statistical 
analysis, 2-tail t-test is performed. n.s not significant; ***p<0.001 **p<0.01 *p<0.05    
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Fig.5 PMA stimulation differently modulated the endogenous MICA/B expression in epithelial 
cancer cell lines. Cells were cultivated in vitro for 24 hours with (grey columns) or without (white 
columns) PMA (50-100 ng/ml). Cellular lysates were analyzed for the amount of MICA (left) and MICB 
(right) by ELISA. One experiment out of three is shown.  
 
 Fig.6 PMA-induced expression of MICA is 
abolished by Cycloheximide (CHX) in Panc89 cells. 
Panc89 cells were cultivated for 24 hours with 
non-toxic concentrations of PMA (50 ng/ml), CHX 
(0.15 µg/ml) and a combination of both. One 
representative experiment is shown. 
 
 
6.5 The particular role of ADAMs in MICA/B shedding 
 
 The identification of metalloproteases as MICA/B sheddases posed the question which individual 
members of this heterogeneous group of proteases mediate the proteolytic cleavage of endogenous 
MICA/B molecules. The members of A disintegrin And Metalloprotease (ADAM) family are involved in 
the ectodomain shedding of a wide variety of cell surface molecules (Huovila et al., 2005) and 
ADAM10 and ADAM17 have already been implicated in the release of sMICA/B in overexpression 
systems (Waldhauer et al., 2008, Boutet et al., 2009). MDA-MB-231, the mammary cancer cell line 
with the highest shedding rate of MICA and PancTu-I, the pancreatic cancer cell line with the lowest 
shedding rate of MICA were transfected with siRNAs targeting ADAM10 and ADAM17 and 
appropriate control siRNAs. After 72 hours, the medium was changed and the transfected cells were 
further incubated in the presence or absence of PMA for additional 24 hours to address induced 
shedding as well. The efficacy of downregulation was confirmed by western blotting and flow 
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cytometry (Fig.7,8 B). In MDA-MB-231 cells (Fig.7 A) the downregulation of ADAM17 significantly 
decreased the amount of soluble MICA/B, whereas shedding was hardly affected by the 
downregulation of ADAM10. In contrast, in PancTu-I cells (Fig.8 A) both proteases were responsible 
for the shedding of MICB. In case of MICA, downregulation of ADAM17, and not ADAM10 inhibited 
the shedding in PancTu-I cells. Exactly the same picture was observed in the case of PMA-stimulated 
shedding. 
 
Fig.7 ADAM17 is major cause of MICA/B shedding from MDA-MB-231. (A) To define the role of 
ADAM10 and ADAM17 in the shedding of MICA/B MDA-MB-231 cells were transfected with siRNAs 
targeting A Disintegrin And Metalloproteases family members ADAM10 and ADAM17 or with 
scrambled RNA as a control. 72 h after transfection the medium was changed and cells were 
incubated for another 24 hour with or without PMA. The amount of soluble MICA/B released into the 
supernatant was assessed by ELISA and the amount of protein released from control RNA transfected 
cells was set to 100%. (B) The effective silencing of ADAM10/17 was confirmed by Western blotting 
and flow cytometry. Data shown are the mean of three to four independent experiments +/- SEM. 
For statistical analysis, a 2-tail t-test was performed. ***p<0.001 **p<0.01 *p<0.05 
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Fig.8 ADAM10 and 17 revealed to be the major cause of MICA/B shedding from PancTu-I cells. (A) 
To define the role of ADAM10 and ADAM17 in the shedding of MICA/B PancTu-I cells were 
transfected with siRNAs targeting A Disintegrin And Metalloproteases family members ADAM10 and 
ADAM17 or with scrambled RNA as a control. 72 h after transfection the medium was changed and 
cells were incubated for another 24 hour with or without PMA. The amount of soluble MICA/B 
released into the supernatant was assessed by ELISA and the amount of protein released from 
control RNA transfected cells was set to 100%. (B) The effective silencing of ADAM10/17 was 
confirmed by Western blotting and flow cytometry. Data shown are the mean of three to four 
independent experiments +/- SEM. For statistical analysis, a 2-tail t-test is performed. ***p<0.001 
**p<0.01 *p<0.05 
 
In summary, the specific inhibition of ADAM10 and ADAM17 by small interfering RNAs revealed the 
particular role of ADAM17 and/or ADAM10 in the cleavage of endogenous MICA/B molecules.   
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6.6 Sequence based typing of MICA  
 
In order to determine which MICA alleles were expressed in the tested carcinoma cell lines, the 
samples of genomic DNA were sent to the Institute of Transplantation Immunology and Clinical 
Transfusions Medicine in Ulm, Germany (Furst et al., 2011). Sequence-based typing of exon2-5 of 
MICA alleles revealed that all the cells, used in this study were heterozygous for MICA expression. 
Panc89, PancTu-I and MDA-MB-231 cells harbored MICA alleles with the full cytoplasmic part, 
whereas PC-3 cells expressed the truncated form of MICA, (MICA*008:01:01) that lacks the 
cytoplasmic domain (Table 1). (http://www.ebi.ac.uk/imgt/hla/stats.html). 
 
Table 1 Allelic variations of MICA in the tested carcinomas. All but PC-3 cells express MICA full 
cytoplasmic anchor. PC-3 cells harbor one MICA allele *008:01:01 lacking the cytoplasmic tail. 
Panc89 PancTu-I MDA-MB-231 PC-3 
*009:01 *002:01  *004 *008:01:01 MICA alleles 
*027 *009:01 *027 *012:01       MICA alleles 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 43 
 
7. Discussion 
 
The antitumor capacities of cell-bound NKG2D ligands and in contrast, tumor promoting properties of 
cleaved, soluble NKG2D ligands have been described many times and the perspective of targeting the 
proteases responsible for the cleavage of NKG2D ligands has been under intensive investigation. 
Different research groups showed the prominent role of various metalloproteases in this process. 
However, most of the studies have been performed in artificial experimental systems using NKG2D 
ligand over expressing cells, whereas the proteases responsible for the shedding of endogenously 
expressed NKG2D ligands have not been precisely defined. 
 
In this in vitro study we have observed that different carcinoma cells, including mammary, pancreatic 
and prostate carcinomas are constitutively expressing and releasing MICA/B molecules into the 
culture medium. However expression and shedding of MICA/B varies from cell line to cell line. All 
tested carcinomas differentially express MIC molecules on the cell surface and their cell surface 
density is associated to respective shedding activity. In PancTu-I cells, especially MICB expression is 
extremely low and this is accompanied by the release of very low amounts of soluble MICB into the 
medium. In contrast to MICB, MICA expression is overall higher in all but prostate cancer PC-3 cells. 
In this particular cell line, we could not detect soluble MICA in the supernatant, despite cell surface 
expression of this molecule. We hypothesized that the reason for the lack of MICA shedding from PC-
3 cells might be the expression of a truncated allelic variant of MICA as MICA*008 for example, which 
represents the most common MICA allele in Caucasian populations (Zhang et al., 2001). MICA*008 
lacks the cytoplasmic tail resulting in a truncated form of this protein. It is released as a full length 
molecule in exosomes and not shed by the cell surface proteases releasing a soluble ectodomain 
form (Ashiru et al., 2010). The hypothesis that PC-3 cells express the truncated variant of MICA is 
further confirmed by sequence based typing of MICA. Genotyping of the tested carcinomas reveals 
that in contrast to other cells, only PC-3 cells harbor the MICA allele *008:01 and apparently we have 
been unable to detect the MICA-containing exosomes in ELISA. Altogether, this clearly indicates the 
allele-dependent regulation of MICA release. Of note, MICA*008 released in exosomes suppresses 
the NK cell cytotoxicity (Clayton and Tabi, 2005) and promotes tumor immune escape to higher 
extent than the soluble ectodomain part of MICA molecules (Ashiru et al., 2010).  
 
In order to avoid NKG2D-mediated immune surveillance, each genetically heterogeneous tumor cell 
has its own cell-dependent regulating mechanism for controlling MIC expression. However, the exact 
contribution of allelic polymorphism in this process is poorly understood. Recently, Shafi et al have 
 44 
 
shown that intragenic MICA polymorphism affect MICA mRNA expression levels in Chinese hamster 
ovary (CHO) cells (Shafi et al., 2011). However, tumors with lower MIC expression would be more 
resistant to NKG2D-mediated immunosurveillance while tumors expressing truncated alleles of MICA 
might impair the NKG2D-mediated response to a higher extent than tumors expressing MICA with a 
full cytoplasmic part. On the other hand, the fact that the NKG2D receptor binds individual allelic 
variants of MICA with different affinities shows that the expression of alleles with high binding 
affinities (MICA*001 and *007) might be more beneficial for cancer immunosurveillance than the 
expression of alleles with low binding affinities (MICA*004, *008, and *016) (Steinle et al., 2001). 
 
Different in vitro and in vivo model studies have been performed to characterize the NKG2D Ligand 
shedding responsible proteases. In line with previous studies (Waldhauer et al., 2008, Boutet et al., 
2009) using over-expressing cells we were able to show that the cleavage of endogenous MICA/B is 
dependent on metalloprotease family members, in particular on A Disintegrin and Metalloproteases 
(ADAM) ADAM10/17. Aspartate, cysteine or serine proteases do not contribute to the cleavage of 
endogenous MICA and MICB molecules. Moreover, the broad range inhibition of metalloproteases 
and specific targeting of ADAM10/17 by siRNA-mediated downregulation increases the cell surface 
expression of MICA/B and therefore the immunogenicity of tumors. However, despite the complete 
abrogation of MICB release from MDA-MB-231 and PancTu-I cells lines by broad range inhibition of 
metalloproteases, it is almost impossible to observe the increase in MICB cell surface expression. Of 
note, PMA, which is a well-known stimulator of ectodomain shedding, is incapable of further 
stimulating MICB release in the same cells, indicating another unknown, cell- or allele-specific 
regulatory mechanism of MICB expression. Once again, inhibition of metalloproteases fails to 
increase the cell surface density of MICA in PC-3 cells expressing MICA*008, which confirms the 
metalloprotease-independent release of this particular allelic variant of MICA.  
 
SiRNA-mediated inhibition of ADAM10/17 in PancTu-I and MDA-MB-231 cells has shown a 
remarkable degree of heterogeneity in MICA/B shedding. MICA shedding is mainly caused by 
ADAM17, whereas both ADAM10 and ADAM17 are responsible for the cleavage of MICB in PancTu-I 
cells indicating a high degree of variability in terms of protease-substrate specificity. Apart from 
ADAM10/17 one cannot exclude that other metalloproteases might play a role in the shedding of 
MICA/B. For instance MMP-9 (Sun et al., 2011), MMP-14 (Liu et al., 2010) and ADAM-9 (Kohga et al., 
2010) have been reported as mediators of MICA shedding in various types of cancer cells. The 
diversity of MIC shedding responsible proteases points out the need of further investigation of this 
complex shedding machinery for the specific targeting of MIC cleavage and for the development of 
more effective therapeutic strategies based on the blocking of NKG2D ligand shedding.  
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Due to the tumor promoting properties of metalloproteases (Duffy et al., 2011),  the therapeutic 
potential of their inhibitors in cancer treatment has been broadly investigated. In contrast to 
successful preclinical testing of these agents (Wilson et al., 1997, Stetler-Stevenson, 1999, Huang et 
al., 2011) the significant evidence of efficacy has not been observed in clinical trials due to their high 
toxicity and the lack of both specificity and selectivity (Fingleton, 2007). Furthermore, none of the 
ADAM17 inhibitors have passed a Phase II clinical trial for similar reasons (DasGupta et al., 2009). 
Nevertheless, a new generation of synthetic, low molecular weight inhibitors targeting ADAM10/17 
specifically, for example INCB7839 (Fridman et al., 2007), are well tolerated and have been shown to 
inhibit tumor cell growth in several preclinical models (Zhou et al., 2006). Currently these agents are 
undergoing clinical investigations in breast cancer patients. Preliminary reports of these studies show 
a promising clinical activity of INCB7839 as a single therapeutic agent as well as in combination with 
EGFR-targeting immunotherapies (Infante et al. 2007). Antitumor activity of INCB7839 might partially 
depend on the inhibition of NKG2D ligand shedding. These specific inhibitors of ADAM10/17 
represent the perfect tool for targeting MICA/B shedding and clinical use of these compounds might 
improve NKG2D-based cancer immunosurveillance and immunotherapy.  
 
Different therapeutic strategies have been proposed to boost the NKG2D system-mediated cancer 
immunosurveillance including the removal of soluble MICA by neutralizing antibodies (Jinushi et al., 
2006) or usage of ex vivo expanded cytokine-induced killer (CIK) cells targeting tumor cells based on 
their NKG2D receptor ligation (Leemhuis et al., 2005, Linn and Hui, 2010).  However, this type of 
treatment would not be effective in patients with low or no MICA/B expression. Therefore, we 
assume that the selection of patient populations with lower expression of NKG2D ligands and 
pretreatment with selective ADAM10/17 inhibitors might improve the clinical outcome of NKG2D-
system based immunotherapies. On the other hand, patients harboring truncated allelic variants of 
MICA would not benefit from this type of treatment. Nevertheless, the contribution of other NKG2D 
ligands in cancer immunosurveillance must be considered as well.  
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8. Summary 
 
The interaction of the MHC class 1-related chain molecules (MIC) A and B with the corresponding 
Natural Killer Group 2D receptor elicits cytotoxicity of Natural Killer cells and T cell subsets. Albeit 
absent in normal tissue, these molecules are constitutively expressed on transformed cells and play 
an important role in tumor immunosurveillance. Consequently, the ectodomain shedding of MICA 
and MICB is regarded as an important mechanism of the immune escape of cancer cells. However, 
the proteolytic machinery responsible for the shedding of endogenous MICA/MICB from tumors has 
not been well defined.   
 
In this study, we analyzed different human tumor entities including mammary, pancreatic and 
prostate carcinomas for the expression and shedding of endogenous MICA and MICB molecules. Flow 
cytometry and ELISA revealed that all the tested cells constitutively expressed MICA and MICB on the 
cell surface and also released NKG2D ligands into the supernatant. Inhibitor studies showed that 
metalloproteases are responsible for both the constitutive and phorbolester-induced generation of 
soluble MICA/B, whereas aspartate, cysteine and serine proteases are not involved in this process. 
Consequently, the inhibition of metalloproteases reduced the level of released MICA/B and increased 
cell surface expression. In the prostate carcinoma cell line PC-3, MICA was not shed at all, despite 
expression of these molecules on the cell surface. Genotyping of this cell line showed that the reason 
for this discrepancy was the expression of the truncated allelic variant, MICA*008:01, indicating an 
allele-specific regulation of this process. Studies employing RNA interference not only revealed a 
prominent role of a disintegrin and metalloprotease (ADAM) 10 and 17 in the shedding of NKG2D 
ligands but also a differential susceptibility of MICA to the proteolytic activity of ADAM10/17. 
 
Altogether, inhibition of shedding responsible proteases lowers the release of tumor-promoting 
soluble MICA/B and increases the cell surface density of these molecules and in that way presumably 
also the immunogenic potential of tumors. The detailed analysis of the proteolytic machinery 
responsible for the shedding of NKG2D ligands such as MICA/B from tumor cells might open the field 
for new strategies in tumor therapy.   
 
 
 
 
 47 
 
9. References 
ALLINSON, T. M., PARKIN, E. T., CONDON, T. P., SCHWAGER, S. L., STURROCK, E. 
D., TURNER, A. J. & HOOPER, N. M. 2004. The role of ADAM10 and ADAM17 in 
the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor 
protein. Eur J Biochem, 271, 2539-47. 
ANDERS, A., GILBERT, S., GARTEN, W., POSTINA, R. & FAHRENHOLZ, F. 2001. 
Regulation of the alpha-secretase ADAM10 by its prodomain and proprotein 
convertases. FASEB J, 15, 1837-9. 
ARRIBAS, J. & BORROTO, A. 2002. Protein ectodomain shedding. Chem Rev, 102, 4627-
38. 
ARRIBAS, J., COODLY, L., VOLLMER, P., KISHIMOTO, T. K., ROSE-JOHN, S. & 
MASSAGUE, J. 1996. Diverse cell surface protein ectodomains are shed by a system 
sensitive to metalloprotease inhibitors. J Biol Chem, 271, 11376-82. 
ASHIRU, O., BOUTET, P., FERNANDEZ-MESSINA, L., AGUERA-GONZALEZ, S., 
SKEPPER, J. N., VALES-GOMEZ, M. & REYBURN, H. T. 2010. Natural killer cell 
cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is 
shed by tumor cells in exosomes. Cancer Research, 70, 481-9. 
BAHRAM, S., BRESNAHAN, M., GERAGHTY, D. E. & SPIES, T. 1994. A second lineage 
of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci U S 
A, 91, 6259-63. 
BALIGA, B. S., PRONCZUK, A. W. & MUNRO, H. N. 1969. Mechanism of cycloheximide 
inhibition of protein synthesis in a cell-free system prepared from rat liver. J Biol 
Chem, 244, 4480-9. 
BLACK, R. A., RAUCH, C. T., KOZLOSKY, C. J., PESCHON, J. J., SLACK, J. L., 
WOLFSON, M. F., CASTNER, B. J., STOCKING, K. L., REDDY, P., 
SRINIVASAN, S., NELSON, N., BOIANI, N., SCHOOLEY, K. A., GERHART, M., 
DAVIS, R., FITZNER, J. N., JOHNSON, R. S., PAXTON, R. J., MARCH, C. J. & 
CERRETTI, D. P. 1997. A metalloproteinase disintegrin that releases tumour-necrosis 
factor-alpha from cells. Nature, 385, 729-33. 
BOISSEL, N., REA, D., TIENG, V., DULPHY, N., BRUN, M., CAYUELA, J. M., 
ROUSSELOT, P., TAMOUZA, R., LE BOUTEILLER, P., MAHON, F. X., 
STEINLE, A., CHARRON, D., DOMBRET, H. & TOUBERT, A. 2006. BCR/ABL 
oncogene directly controls MHC class I chain-related molecule A expression in 
chronic myelogenous leukemia. J Immunol, 176, 5108-16. 
BOUTET, P., AGUERA-GONZALEZ, S., ATKINSON, S., PENNINGTON, C. J., 
EDWARDS, D. R., MURPHY, G., REYBURN, H. T. & VALES-GOMEZ, M. 2009. 
Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme 
regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol, 
182, 49-53. 
 48 
 
CARL-MCGRATH, S., LENDECKEL, U., EBERT, M., ROESSNER, A. & ROCKEN, C. 
2005. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are 
upregulated in gastric cancer. Int J Oncol, 26, 17-24. 
CASTRICONI, R., CANTONI, C., DELLA CHIESA, M., VITALE, M., MARCENARO, E., 
CONTE, R., BIASSONI, R., BOTTINO, C., MORETTA, L. & MORETTA, A. 2003. 
Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D 
receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad 
Sci U S A, 100, 4120-5. 
CERWENKA, A., BAKKER, A. B., MCCLANAHAN, T., WAGNER, J., WU, J., PHILLIPS, 
J. H. & LANIER, L. L. 2000. Retinoic acid early inducible genes define a ligand 
family for the activating NKG2D receptor in mice. Immunity, 12, 721-7. 
CHALARIS, A., RABE, B., PALIGA, K., LANGE, H., LASKAY, T., FIELDING, C. A., 
JONES, S. A., ROSE-JOHN, S. & SCHELLER, J. 2007. Apoptosis is a natural 
stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling 
function of neutrophils. Blood, 110, 1748-55. 
CHAMPSAUR, M. & LANIER, L. L. 2010. Effect of NKG2D ligand expression on host 
immune responses. Immunol Rev, 235, 267-85. 
CLAYTON, A. & TABI, Z. 2005. Exosomes and the MICA-NKG2D system in cancer. Blood 
Cells Mol Dis, 34, 206-13. 
COLLINS, R. W. 2004. Human MHC class I chain related (MIC) genes: their biological 
function and relevance to disease and transplantation. Eur J Immunogenet, 31, 105-14. 
COOPER, M. A., FEHNIGER, T. A. & CALIGIURI, M. A. 2001. The biology of human 
natural killer-cell subsets. Trends in Immunology, 22, 633-640. 
COUDERT, J. D. & HELD, W. 2006. The role of the NKG2D receptor for tumor immunity. 
Semin Cancer Biol, 16, 333-43. 
DANO, K., BEHRENDT, N., HOYER-HANSEN, G., JOHNSEN, M., LUND, L. R., 
PLOUG, M. & ROMER, J. 2005. Plasminogen activation and cancer. Thromb 
Haemost, 93, 676-81. 
DASGUPTA, S., MURUMKAR, P. R., GIRIDHAR, R. & YADAV, M. R. 2009. Current 
perspective of TACE inhibitors: a review. Bioorg Med Chem, 17, 444-59. 
DUAN, X., DENG, L., CHEN, X., LU, Y., ZHANG, Q., ZHANG, K., HU, Y., ZENG, J. & 
SUN, W. 2011. Clinical significance of the immunostimulatory MHC class I chain-
related molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med 
Oncol, 28, 466-74. 
DUFFY, M. J., MCKIERNAN, E., O'DONOVAN, N. & MCGOWAN, P. M. 2009. Role of 
ADAMS in Cancer Formation and Progression. Clinical Cancer Research, 15, 1140-
1144. 
 49 
 
DUFFY, M. J., MULLOOLY, M., O'DONOVAN, N., SUKOR, S., CROWN, J., PIERCE, A. 
& MCGOWAN, P. M. 2011. The ADAMs family of proteases: new biomarkers and 
therapeutic targets for cancer? Clin Proteomics, 8, 9. 
EAGLE, R. A., JAFFERJI, I. & BARROW, A. D. 2009. Beyond Stressed Self: Evidence for 
NKG2D Ligand Expression on Healthy Cells. Curr Immunol Rev, 5, 22-34. 
EAGLE, R. A. & TROWSDALE, J. 2007. Promiscuity and the single receptor: NKG2D. Nat 
Rev Immunol, 7, 737-44. 
EBIHARA, T., MASUDA, H., AKAZAWA, T., SHINGAI, M., KIKUTA, H., ARIGA, T., 
MATSUMOTO, M. & SEYA, T. 2007. Induction of NKG2D ligands on human 
dendritic cells by TLR ligand stimulation and RNA virus infection. Int Immunol, 19, 
1145-55. 
EISELE, G., WISCHHUSEN, J., MITTELBRONN, M., MEYERMANN, R., 
WALDHAUER, I., STEINLE, A., WELLER, M. & FRIESE, M. A. 2006. TGF-beta 
and metalloproteinases differentially suppress NKG2D ligand surface expression on 
malignant glioma cells. Brain, 129, 2416-25. 
ELEME, K., TANER, S. B., ONFELT, B., COLLINSON, L. M., MCCANN, F. E., 
CHALUPNY, N. J., COSMAN, D., HOPKINS, C., MAGEE, A. I. & DAVIS, D. M. 
2004. Cell surface organization of stress-inducible proteins ULBP and MICA that 
stimulate human NK cells and T cells via NKG2D. Journal of Experimental Medicine, 
199, 1005-10. 
ENGVALL, E. & PERLMANN, P. 1971. Enzyme-linked immunosorbent assay (ELISA). 
Quantitative assay of immunoglobulin G. Immunochemistry, 8, 871-4. 
FAN, H. & DERYNCK, R. 1999. Ectodomain shedding of TGF-alpha and other 
transmembrane proteins is induced by receptor tyrosine kinase activation and MAP 
kinase signaling cascades. EMBO J, 18, 6962-72. 
FERNANDEZ, L., FERNANDEZ-ARQUERO, M., GUAL, L., LAZARO, F., MALUENDA, 
C., POLANCO, I., FIGUEREDO, M. A. & GOMEZ DE LA CONCHA, E. 2002. 
Triplet repeat polymorphism in the transmembrane region of the MICA gene in celiac 
disease. Tissue Antigens, 59, 219-22. 
FINGLETON, B. 2007. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des, 
13, 333-46. 
FRIDMAN, J. S., CAULDER, E., HANSBURY, M., LIU, X., YANG, G., WANG, Q., LO, 
Y., ZHOU, B. B., PAN, M., THOMAS, S. M., GRANDIS, J. R., ZHUO, J., YAO, W., 
NEWTON, R. C., FRIEDMAN, S. M., SCHERLE, P. A. & VADDI, K. 2007. 
Selective inhibition of ADAM metalloproteases as a novel approach for modulating 
ErbB pathways in cancer. Clin Cancer Res, 13, 1892-902. 
FUERTES, M. B., GIRART, M. V., MOLINERO, L. L., DOMAICA, C. I., ROSSI, L. E., 
BARRIO, M. M., MORDOH, J., RABINOVICH, G. A. & ZWIRNER, N. W. 2008. 
Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in 
human melanomas confers immune privilege and prevents NK cell-mediated 
cytotoxicity. J Immunol, 180, 4606-14. 
 50 
 
FURST, D., SOLGI, G., RECKER, K., MYTILINEOS, D., SCHREZENMEIER, H. & 
MYTILINEOS, J. 2011. Sequence-based typing of major histocompatibility complex 
class I chain-related gene A alleles by use of exons 2-5 information. Tissue Antigens, 
77, 201-5. 
GARCIA, G., DEL PUERTO, F., PEREZ, A. B., SIERRA, B., AGUIRRE, E., KIKUCHI, M., 
SANCHEZ, L., HIRAYAMA, K. & GUZMAN, M. G. 2011. Association of MICA 
and MICB alleles with symptomatic dengue infection. Human Immunology, 72, 904-7. 
GARTON, K. J., GOUGH, P. J. & RAINES, E. W. 2006. Emerging roles for ectodomain 
shedding in the regulation of inflammatory responses. Journal of Leukocyte Biology, 
79, 1105-1116. 
GASSER, S., ORSULIC, S., BROWN, E. J. & RAULET, D. H. 2005. The DNA damage 
pathway regulates innate immune system ligands of the NKG2D receptor. Nature, 
436, 1186-90. 
GIALELI, C., THEOCHARIS, A. D. & KARAMANOS, N. K. 2011. Roles of matrix 
metalloproteinases in cancer progression and their pharmacological targeting. FEBS J, 
278, 16-27. 
GLOZAK, M. A. & SETO, E. 2007. Histone deacetylases and cancer. Oncogene, 26, 5420-
32. 
GONZALEZ, S., LOPEZ-SOTO, A., SUAREZ-ALVAREZ, B., LOPEZ-VAZQUEZ, A. & 
LOPEZ-LARREA, C. 2008. NKG2D ligands: key targets of the immune response. 
Trends Immunol, 29, 397-403. 
GONZALEZ, S., MARTINEZ-BORRA, J., TORRE-ALONSO, J. C., GONZALEZ-ROCES, 
S., SANCHEZ DEL RIO, J., RODRIGUEZ PEREZ, A., BRAUTBAR, C. & LOPEZ-
LARREA, C. 1999. The MICA-A9 triplet repeat polymorphism in the transmembrane 
region confers additional susceptibility to the development of psoriatic arthritis and is 
independent of the association of Cw*0602 in psoriasis. Arthritis Rheum, 42, 1010-6. 
GROH, V., RHINEHART, R., RANDOLPH-HABECKER, J., TOPP, M. S., RIDDELL, S. R. 
& SPIES, T. 2001. Costimulation of CD8alphabeta T cells by NKG2D via 
engagement by MIC induced on virus-infected cells. Nat Immunol, 2, 255-60. 
GROH, V., RHINEHART, R., SECRIST, H., BAUER, S., GRABSTEIN, K. H. & SPIES, T. 
1999. Broad tumor-associated expression and recognition by tumor-derived gamma 
delta T cells of MICA and MICB. Proc Natl Acad Sci U S A, 96, 6879-84. 
GROH, V., SMYTHE, K., DAI, Z. & SPIES, T. 2006. Fas-ligand-mediated paracrine T cell 
regulation by the receptor NKG2D in tumor immunity. Nat Immunol, 7, 755-62. 
GROH, V., WU, J., YEE, C. & SPIES, T. 2002. Tumour-derived soluble MIC ligands impair 
expression of NKG2D and T-cell activation. Nature, 419, 734-738. 
GUERRA, N., TAN, Y. X., JONCKER, N. T., CHOY, A., GALLARDO, F., XIONG, N., 
KNOBLAUGH, S., CADO, D., GREENBERG, N. M. & RAULET, D. H. 2008. 
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous 
malignancy. Immunity, 28, 571-80. 
 51 
 
HAMERMAN, J. A., OGASAWARA, K. & LANIER, L. L. 2004. Cutting edge: Toll-like 
receptor signaling in macrophages induces ligands for the NKG2D receptor. J 
Immunol, 172, 2001-5. 
HIGASHIYAMA, S., NANBA, D., NAKAYAMA, H., INOUE, H. & FUKUDA, S. 2011. 
Ectodomain shedding and remnant peptide signalling of EGFRs and their ligands. J 
Biochem, 150, 15-22. 
HOLDENRIEDER, S., STIEBER, P., PETERFI, A., NAGEL, D., STEINLE, A. & SALIH, 
H. R. 2006. Soluble MICA in malignant diseases. Int J Cancer, 118, 684-7. 
HOOPER, N. M., KARRAN, E. H. & TURNER, A. J. 1997. Membrane protein secretases. 
Biochem J, 321 ( Pt 2), 265-79. 
HUANG, B., SIKORSKI, R., SAMPATH, P. & THORNE, S. H. 2011. Modulation of 
NKG2D-ligand cell surface expression enhances immune cell therapy of cancer. J 
Immunother, 34, 289-96. 
HUANG, Y., LEE, Y. J., CHEN, M. R., HSU, C. H., LIN, S. P., SUNG, T. C., CHANG, S. C. 
& CHANG, J. G. 2000. Polymorphism of transmembrane region of MICA gene and 
Kawasaki disease. Exp Clin Immunogenet, 17, 130-7. 
HUOVILA, A. P., TURNER, A. J., PELTO-HUIKKO, M., KARKKAINEN, I. & ORTIZ, R. 
M. 2005. Shedding light on ADAM metalloproteinases. Trends Biochem Sci, 30, 413-
22. 
 
INFANTE, J., BURRIS, HA., LEWIS, N., 2007, 106(Supp1):S269  A multicenter phase Ib 
study of the safety, pharmacokinetics, biological activity and clinical efficacy of 
INCB7839, a potent and selective inhibitor of ADAM10 and ADAM17. Breast 
Cancer Res Treat 
 
JANES, P. W., SAHA, N., BARTON, W. A., KOLEV, M. V., WIMMER-KLEIKAMP, S. H., 
NIEVERGALL, E., BLOBEL, C. P., HIMANEN, J. P., LACKMANN, M. & 
NIKOLOV, D. B. 2005. Adam meets Eph: an ADAM substrate recognition module 
acts as a molecular switch for ephrin cleavage in trans. Cell, 123, 291-304 
 
JINUSHI, M., HODI, F. S. & DRANOFF, G. 2006. Therapy-induced antibodies to MHC 
class I chain-related protein A antagonize immune suppression and stimulate 
antitumor cytotoxicity. Proc Natl Acad Sci U S A, 103, 9190-5. 
 
JINUSHI, M., TAKEHARA, T., KANTO, T., TATSUMI, T., GROH, V., SPIES, T., 
MIYAGI, T., SUZUKI, T., SASAKI, Y. & HAYASHI, N. 2003. Critical role of MHC 
class I-related chain A and B expression on IFN-alpha-stimulated dendritic cells in NK 
cell activation: impairment in chronic hepatitis C virus infection. J Immunol, 170, 
1249-56. 
 
KATO, N., TANAKA, J., SUGITA, J., TOUBAI, T., MIURA, Y., IBATA, M., SYONO, Y., 
OTA, S., KONDO, T., ASAKA, M. & IMAMURA, M. 2007. Regulation of the 
expression of MHC class I-related chain A, B (MICA, MICB) via chromatin 
remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of 
NKG2D-expressing cells. Leukemia, 21, 2103-8. 
 52 
 
KELLNER, C., HALLACK, D., GLORIUS, P., STAUDINGER, M., MOHSENI NODEHI, 
S., DE WEERS, M., VAN DE WINKEL, J. G., PARREN, P. W., STAUCH, M., 
VALERIUS, T., REPP, R., HUMPE, A., GRAMATZKI, M. & PEIPP, M. 2012. 
Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable 
fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance 
antibody-dependent cellular cytotoxicity. Leukemia, 26, 830-4. 
KHANNA, R. 1998. Tumour surveillance: missing peptides and MHC molecules. Immunol 
Cell Biol, 76, 20-6. 
KIESSLING, R., KLEIN, E. & WIGZELL, H. 1975. "Natural" killer cells in the mouse. I. 
Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and 
distribution according to genotype. Eur J Immunol, 5, 112-7. 
KOHGA, K., TAKEHARA, T., TATSUMI, T., ISHIDA, H., MIYAGI, T., HOSUI, A. & 
HAYASHI, N. 2010. Sorafenib inhibits the shedding of major histocompatibility 
complex class I-related chain A on hepatocellular carcinoma cells by down-regulating 
a disintegrin and metalloproteinase 9. Hepatology, 51, 1264-73. 
LAEMMLI, U. K. 1970. Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature, 227, 680-5. 
LANIER, L. L. 2001. A renaissance for the tumor immunosurveillance hypothesis. Nat Med, 
7, 1178-80. 
LEE, J. C., LEE, K. M., KIM, D. W. & HEO, D. S. 2004. Elevated TGF-beta1 secretion and 
down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J 
Immunol, 172, 7335-40. 
LEEMHUIS, T., WELLS, S., SCHEFFOLD, C., EDINGER, M. & NEGRIN, R. S. 2005. A 
phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed 
Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant, 11, 
181-7. 
LENDECKEL, U., KOHL, J., ARNDT, M., CARL-MCGRATH, S., DONAT, H. & 
ROCKEN, C. 2005. Increased expression of ADAM family members in human breast 
cancer and breast cancer cell lines. J Cancer Res Clin Oncol, 131, 41-8. 
LINN, Y. C. & HUI, K. M. 2010. Cytokine-induced NK-like T cells: from bench to bedside. J 
Biomed Biotechnol, 2010, 435745. 
LIST, K., BUGGE, T. H. & SZABO, R. 2006. Matriptase: potent proteolysis on the cell 
surface. Mol Med, 12, 1-7. 
LIU, G., ATTERIDGE, C. L., WANG, X., LUNDGREN, A. D. & WU, J. D. 2010. The 
membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of 
MHC class I chain-related molecule A independent of A disintegrin and 
metalloproteinases. J Immunol, 184, 3346-50. 
LOPEZ-LARREA, C., SUAREZ-ALVAREZ, B., LOPEZ-SOTO, A., LOPEZ-VAZQUEZ, A. 
& GONZALEZ, S. 2008. The NKG2D receptor: sensing stressed cells. Trends Mol 
Med, 14, 179-89. 
 53 
 
LU, X., LU, D., SCULLY, M. & KAKKAR, V. 2008. ADAM proteins - therapeutic potential 
in cancer. Curr Cancer Drug Targets, 8, 720-32. 
LUCI, C. & TOMASELLO, E. 2008. Natural killer cells: detectors of stress. Int J Biochem 
Cell Biol, 40, 2335-40. 
 
MURPHY, K., TRAVERS, P., WALPORT, M., Janeway's Immunobiology. 2008 
 
NICE, T. J., COSCOY, L. & RAULET, D. H. 2009. Posttranslational regulation of the 
NKG2D ligand Mult1 in response to cell stress. Journal of Experimental Medicine, 
206, 287-98. 
 
OKITA, R., MOUGIAKAKOS, D., ANDO, T., MAO, Y., SARHAN, D., WENNERBERG, 
E., SELIGER, B., LUNDQVIST, A., MIMURA, K. & KIESSLING, R. 2012. 
HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I 
chain-related molecule A and B expression in human breast cancer cell lines. J 
Immunol, 188, 2136-45. 
 
PAN, D. & RUBIN, G. M. 1997. Kuzbanian controls proteolytic processing of Notch and 
mediates lateral inhibition during Drosophila and vertebrate neurogenesis. Cell, 90, 
271-80. 
 
PENDE, D., RIVERA, P., MARCENARO, S., CHANG, C. C., BIASSONI, R., CONTE, R., 
KUBIN, M., COSMAN, D., FERRONE, S., MORETTA, L. & MORETTA, A. 2002. 
Major histocompatibility complex class I-related chain a and UL16-binding protein 
expression on tumor cell lines of different histotypes: Analysis of tumor susceptibility 
to NKG2D-dependent natural killer cell cytotoxicity. Cancer Research, 62, 6178-
6186. 
 
PESCHON, J. J., SLACK, J. L., REDDY, P., STOCKING, K. L., SUNNARBORG, S. W., 
LEE, D. C., RUSSELL, W. E., CASTNER, B. J., JOHNSON, R. S., FITZNER, J. N., 
BOYCE, R. W., NELSON, N., KOZLOSKY, C. J., WOLFSON, M. F., RAUCH, C. 
T., CERRETTI, D. P., PAXTON, R. J., MARCH, C. J. & BLACK, R. A. 1998. An 
essential role for ectodomain shedding in mammalian development. Science, 282, 
1281-4. 
 
RABINOVICH, B. A., LI, J., SHANNON, J., HURREN, R., CHALUPNY, J., COSMAN, D. 
& MILLER, R. G. 2003. Activated, but not resting, T cells can be recognized and 
killed by syngeneic NK cells. J Immunol, 170, 3572-6. 
 
RAULET, D. H. 2003. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev 
Immunol, 3, 781-90. 
 
REDDY, P., SLACK, J. L., DAVIS, R., CERRETTI, D. P., KOZLOSKY, C. J., BLANTON, 
R. A., SHOWS, D., PESCHON, J. J. & BLACK, R. A. 2000. Functional analysis of 
the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem, 
275, 14608-14. 
 
REISS, K. & SAFTIG, P. 2009. The "a disintegrin and metalloprotease" (ADAM) family of 
sheddases: physiological and cellular functions. Semin Cell Dev Biol, 20, 126-37. 
 54 
 
RINCON-OROZCO, B., KUNZMANN, V., WROBEL, P., KABELITZ, D., STEINLE, A. & 
HERRMANN, T. 2005. Activation of V gamma 9V delta 2 T cells by NKG2D. J 
Immunol, 175, 2144-51. 
 
SAHIN, U., WESKAMP, G., KELLY, K., ZHOU, H. M., HIGASHIYAMA, S., PESCHON, 
J., HARTMANN, D., SAFTIG, P. & BLOBEL, C. P. 2004. Distinct roles for 
ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol, 
164, 769-79. 
 
SALIH, H. R., ANTROPIUS, H., GIESEKE, F., LUTZ, S. Z., KANZ, L., RAMMENSEE, H. 
G. & STEINLE, A. 2003. Functional expression and release of ligands for the 
activating immunoreceptor NKG2D in leukemia. Blood, 102, 1389-96. 
 
SALIH, H. R., RAMMENSEE, H. G. & STEINLE, A. 2002. Cutting edge: down-regulation 
of MICA on human tumors by proteolytic shedding. J Immunol, 169, 4098-102. 
 
SCHAFER, B., GSCHWIND, A. & ULLRICH, A. 2004. Multiple G-protein-coupled receptor 
signals converge on the epidermal growth factor receptor to promote migration and 
invasion. Oncogene, 23, 991-9. 
 
SCHULTE, M., REISS, K., LETTAU, M., MARETZKY, T., LUDWIG, A., HARTMANN, 
D., DE STROOPER, B., JANSSEN, O. & SAFTIG, P. 2007. ADAM10 regulates FasL 
cell surface expression and modulates FasL-induced cytotoxicity and activation-
induced cell death. Cell Death Differ, 14, 1040-9. 
 
SCHWINN, N., VOKHMINOVA, D., SUCKER, A., TEXTOR, S., STRIEGEL, S., MOLL, 
I., NAUSCH, N., TUETTENBERG, J., STEINLE, A., CERWENKA, A., 
SCHADENDORF, D. & PASCHEN, A. 2009. Interferon-gamma down-regulates 
NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class 
I-deficient melanoma by natural killer cells. Int J Cancer, 124, 1594-604. 
 
SEALS, D. F. & COURTNEIDGE, S. A. 2003. The ADAMs family of metalloproteases: 
multidomain proteins with multiple functions. Genes Dev, 17, 7-30. 
 
SHAFI, S., VANTOUROUT, P., WALLACE, G., ANTOUN, A., VAUGHAN, R., 
STANFORD, M. & HAYDAY, A. 2011. An NKG2D-mediated human lymphoid 
stress surveillance response with high interindividual variation. Sci Transl Med, 3, 
113ra124. 
 
SIX, E., NDIAYE, D., LAABI, Y., BROU, C., GUPTA-ROSSI, N., ISRAEL, A. & 
LOGEAT, F. 2003. The Notch ligand Delta1 is sequentially cleaved by an ADAM 
protease and gamma-secretase. Proc Natl Acad Sci U S A, 100, 7638-43. 
 
SLOANE, B. F., YAN, S. Q., PODGORSKI, I., LINEBAUGH, B. E., CHER, M. L., MAI, J. 
X., CAVALLO-MEDVED, D., SAMENI, M., DOSESCU, J. & MOIN, K. 2005. 
Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment. 
Seminars in Cancer Biology, 15, 149-157. 
 
 55 
 
SMYTH, M. J., SWANN, J., CRETNEY, E., ZERAFA, N., YOKOYAMA, W. M. & 
HAYAKAWA, Y. 2005. NKG2D function protects the host from tumor initiation. 
Journal of Experimental Medicine, 202, 583-588. 
 
SPIES, T. 2008. Regulation of NKG2D ligands: a purposeful but delicate affair. Nat Immunol, 
9, 1013-5. 
 
STEINLE, A., LI, P., MORRIS, D. L., GROH, V., LANIER, L. L., STRONG, R. K. & 
SPIES, T. 2001. Interactions of human NKG2D with its ligands MICA, MICB, and 
homologs of the mouse RAE-1 protein family. Immunogenetics, 53, 279-87. 
 
STEPHENS, H. A. 2001. MICA and MICB genes: can the enigma of their polymorphism be 
resolved? Trends Immunol, 22, 378-85. 
 
STERN-GINOSSAR, N. & MANDELBOIM, O. 2009. An integrated view of the regulation 
of NKG2D ligands. Immunology, 128, 1-6. 
 
STETLER-STEVENSON, W. G. 1999. Matrix metalloproteinases in angiogenesis: a moving 
target for therapeutic intervention. J Clin Invest, 103, 1237-41. 
 
SUN, D., WANG, X., ZHANG, H., DENG, L. & ZHANG, Y. 2011. MMP9 mediates MICA 
shedding in human osteosarcomas. Cell Biol Int, 35, 569-74. 
 
THOMAS, M., WILLS, M. & LEHNER, P. J. 2008. Natural killer cell evasion by an E3 
ubiquitin ligase from Kaposi's sarcoma-associated herpesvirus. Biochem Soc Trans, 
36, 459-63. 
 
TOKUMARU, S., HIGASHIYAMA, S., ENDO, T., NAKAGAWA, T., MIYAGAWA, J. I., 
YAMAMORI, K., HANAKAWA, Y., OHMOTO, H., YOSHINO, K., SHIRAKATA, 
Y., MATSUZAWA, Y., HASHIMOTO, K. & TANIGUCHI, N. 2000. Ectodomain 
shedding of epidermal growth factor receptor ligands is required for keratinocyte 
migration in cutaneous wound healing. J Cell Biol, 151, 209-20. 
 
TRINCHIERI, G. 1989. Biology of natural killer cells. Adv Immunol, 47, 187-376. 
 
ENKATARAMAN, G. M., SUCIU, D., GROH, V., BOSS, J. M. & SPIES, T. 2007. Promoter 
region architecture and transcriptional regulation of the genes for the MHC class I-
related chain A and B ligands of NKG2D. J Immunol, 178, 961-9. 
 
VERNERIS, M. R., KARAMI, M., BAKER, J., JAYASWAL, A. & NEGRIN, R. S. 2004. 
Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. 
Blood, 103, 3065-72. 
 
VESELY, M. D., KERSHAW, M. H., SCHREIBER, R. D. & SMYTH, M. J. 2011. Natural 
innate and adaptive immunity to cancer. Annu Rev Immunol, 29, 235-71. 
 
VIVIER, E., RAULET, D. H., MORETTA, A., CALIGIURI, M. A., ZITVOGEL, L., 
LANIER, L. L., YOKOYAMA, W. M. & UGOLINI, S. 2011. Innate or adaptive 
immunity? The example of natural killer cells. Science, 331, 44-9. 
 56 
 
VIVIER, E., TOMASELLO, E., BARATIN, M., WALZER, T. & UGOLINI, S. 2008. 
Functions of natural killer cells. Nat Immunol, 9, 503-10. 
 
WALDHAUER, I., GOEHLSDORF, D., GIESEKE, F., WEINSCHENK, T., 
WITTENBRINK, M., LUDWIG, A., STEVANOVIC, S., RAMMENSEE, H. G. & 
STEINLE, A. 2008. Tumor-associated MICA is shed by ADAM proteases. Cancer 
Research, 68, 6368-76. 
 
WALDHAUER, I. & STEINLE, A. 2008. NK cells and cancer immunosurveillance. 
Oncogene, 27, 5932-43. 
WEISS-STEIDER, B., SOTO-CRUZ, I., MARTINEZ-CAMPOS, C. A. & MENDOZA-
RINCON, J. F. 2011. Expression of MICA, MICB and NKG2D in human leukemic 
myelomonocytic and cervical cancer cells. Journal of Experimental & Clinical Cancer 
Research, 30. 
WILSON, C. L., HEPPNER, K. J., LABOSKY, P. A., HOGAN, B. L. & MATRISIAN, L. M. 
1997. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase 
matrilysin. Proc Natl Acad Sci U S A, 94, 1402-7. 
YAN, R., BIENKOWSKI, M. J., SHUCK, M. E., MIAO, H., TORY, M. C., PAULEY, A. M., 
BRASHIER, J. R., STRATMAN, N. C., MATHEWS, W. R., BUHL, A. E., CARTER, 
D. B., TOMASSELLI, A. G., PARODI, L. A., HEINRIKSON, R. L. & GURNEY, M. 
E. 1999. Membrane-anchored aspartyl protease with Alzheimer's disease beta-
secretase activity. Nature, 402, 533-7. 
ZHANG, C., WANG, Y. P., ZHOU, Z. X., ZHANG, J. & TIAN, Z. G. 2009. Sodium butyrate 
upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and 
increases their susceptibility to NK lysis. Cancer Immunology Immunotherapy, 58, 
1275-1285. 
ZHANG, Y., LAZARO, A. M., LAVINGIA, B. & STASTNY, P. 2001. Typing for all known 
MICA alleles by group-specific PCR and SSOP. Human Immunology, 62, 620-31. 
ZHOU, B. B., PEYTON, M., HE, B., LIU, C., GIRARD, L., CAUDLER, E., LO, Y., 
BARIBAUD, F., MIKAMI, I., REGUART, N., YANG, G., LI, Y., YAO, W., VADDI, 
K., GAZDAR, A. F., FRIEDMAN, S. M., JABLONS, D. M., NEWTON, R. C., 
FRIDMAN, J. S., MINNA, J. D. & SCHERLE, P. A. 2006. Targeting ADAM-
mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung 
cancer. Cancer Cell, 10, 39-50. 
 
 
 
 
 
 
 57 
 
9. Acknowledgements 
 
I would like to express deepest gratitude to my supervisor and mentor Prof. Dr. med. Dieter Kabelitz 
who gave me the chance to work in the Institute of Immunology on this fascinating research project. I 
am very grateful for encouragement and continuous help he has provided throughout my time as his 
student. I deeply appreciate his valuable and constructive suggestions during the planning and 
development of this research work. I wish also to express my sincere thanks to my co-supervisors 
Prof. Grötzinger and Dr. Chalaris for the important academic support. 
I would like to express my admiration to Dr. Marcus Lettau who invested a lot of his time and effort 
in this work to reach its final form. I am extremely grateful for his esteem opinions and valuable 
remarks. 
I would like to thank PD. Dr. Daniela Wesch and Dr. Heiner Oberg and express my great appreciation 
for initiating this project and for their substantial support all the time.  
I am very grateful to my entire group and the members of the institute of immunology for creating 
wonderful working environment. Completing this work would have been more difficult if not the 
technical support provided from the staff of the laboratory of institute of immunology. Special thanks 
to Sandra Ussat, Hoa Ly and Signe Valentine for perfect assistance and to Jaydeep Bhat, PhD student 
of this project for his kind support in immuneprecipitation of MICA. 
I express my gratitude to Prof. Kalthoff from the Institute for Experimental Cancer Research, (Kiel, 
Germany) for the cell lines, which he kindly provided and to Prof. Mytilineos from the Institute of 
Clinical Transfusion Medicine and Immunogenetics, (Ulm, Germany) for the support in MICA 
genotyping. 
I would like to thank the Collaborative Research Center (CRC) 877 „Proteolysis as a Regulatory Event 
in Pathophysiology” and integrated research training group (IRTG), not only for providing the funding 
which allowed me to undertake this research, but also for giving me the opportunity to attend 
conferences and present my work there.  
 
 
 
 
 
 
 58 
 
10. CV 
Guranda Chitadze 
Hindenburgufer 78/79 Kiel, Germany, 24105 
Phone: +4915775113308 
E-mail: gurandachitadze@gmail.com 
 
 
 
 
Professional and Scientific Experience 
April 2011 - June 2012 
· Doctoral thesis in the Institute of Immunology, Kiel, Germany 
October 2010 - March 2011 
· Research Grant Award for Doctoral Candidates and Young Academics and Scientists 
(DAAD) 
June 2009 - September 2010 
· Internship in the laboratory of the Institute of Microbiology and biotechnology, Tbilisi, 
Georgia 
 
 
Education 
October 2010 - Present 
· Promotion student at the University of Kiel, Institute of Immunology, Germany 
In frame of the Collaborative Research Center (CRC) 877, Project A7, Expression and 
shedding of MICA and MICB molecules in different human tumor entities (Supervisor Prof. 
Dr. med. D. Kabelitz) 
February 2008 - June 2010 
· Allergy and Immunology residency program at the department of Allergology and 
Immunology at Tbilisi State Medical University Hospital 
September 2000 - June 2006 
· Tbilisi State Medical University (Faculty of Medicine) 
 
 
 59 
 
 
Scientific Trainings and Courses 
· Autumn School of Immunology, Bad Schandau, Germany 2011 
· Career planning for PhD students, Kiel, 2012 (CAU) 
· Writing a scientific publication, Kiel, 2012 (CAU) 
· 1st Baltic Mass Spectrometry Meeting, Kiel 2011 - From Bacteria to Disease (CAU) 
· "Advanced Microscopy", Kiel 2011 (CAU) 
· Proteomics 2.0 Initiative 2011, Kiel (CAU) 
· Applied Bioinformatics, Hamburg, 2011(UKE) 
· Statistics for natural scientists, Kiel 2010/2011 (CAU) 
· Access a New World of RNAi-based Discovery, Kiel, 2011 
 
Symposiums 
· Proteases and Pathophysiology, IRTG symposium, 26-27 September, 2011 Kiel, Germany 
(Poster Presentation) (Integrated Research Training Group) 
· Joint Annual Meeting 28.09.2011-01.10.2011, Riccione, Italy (Poster Presentation) 
(Italian Society for Immunology Clinical Immunology and Allergology (SIICA) and German 
Society for Immunology (DGfI)) 
· Fifth International Gamma-Delta T-Cell Conference, Freiburg, 31.05.2012-02.06.2012, 
Germany  
 
Language skills 
· English-fluently 
· German-fluently 
· Russian-fluently 
· Georgian-native 
 
 
June, 2012                                                 Guranda Chitadze 
Kiel, Germany 
 
